

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Risks and benefits of urinary catheterisation during inpatient diuretic therapy for acute congestive heart failure: A retrospective, non-inferiority, cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-053632
Article Type:	Original research
Date Submitted by the Author:	18-May-2021
Complete List of Authors:	John, Gregor; Hôpitaux Universitaires Genève, Department of Internal Medicine; Université de Genève, Department of Medicine Arcens, Marc; Hôpitaux Universitaires Genève, Department of Medicine Berra, Gregory; Hôpitaux Universitaires Genève, Department of Medicine Garin, Nicolas; Hôpitaux Universitaires Genève, Department of Medicine; Université de Genève Carballo, David ; Université de Genève; Hôpitaux Universitaires Genève, Department of Medicine Carballo, Sebastian; Hôpitaux Universitaires Genève, Department of Medicine; Université de Genève Stirnemann, Jerome; Hôpitaux Universitaires Genève, Department of Medicine; Université de Genève
Keywords:	Heart failure < CARDIOLOGY, Urinary tract infections < UROLOGY, Health & safety < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1 **Title:** Risks and benefits of urinary catheterisation during inpatient
2
3
4 diuretic therapy for acute congestive heart failure: A retrospective, non-
5
6 inferiority, cohort study
7
8
9

10 **Running headline:** urinary catheterisation in acute heart failure.
11
12
13

14 Gregor John^{1,2,3*}, Marc Arcens², Gregory Berra², Nicolas Garin^{2,3}, David Carballo^{3,4},
15
16 Sebastian Carballo^{2,3}, Jérôme Stirnemann^{2,3}.
17
18
19
20

21 1. Department of Internal Medicine, Neuchâtel Hospital Network, Rue de la Maladière
22
23 45, CH-2000 Neuchâtel, Switzerland
24
25

26 2. Department of Medicine, Geneva University Hospitals (HUG), Gabrielle-Perret-
27
28 Gentil 4, CH-1205 Geneva, Switzerland; Fax: 0041 32 967 27 29, Phone: 0041 79
29
30 559 59 29; gregor.john@h-ne.ch (may be published).
31
32

33 3. Geneva university, Michel-Servet 1, 1211 Genève 4, Switzerland.
34

35 4. Cardiology Service, Department of Medicine, Geneva University Hospitals (HUG),
36
37 Gabrielle-Perret-Gentil 4, CH-1205 Geneva, david.carballo@hcuge.ch
38
39
40
41

42 ***Gregor John^{1,2,3*}**, PD, MD (correspondence and requests for reprints); Department
43
44 of Internal Medicine, Neuchâtel Hospital Network, Rue de la Maladière 45, CH-2000
45
46 Neuchâtel, Switzerland. Fax: 0041 32 967 27 29, Phone: 0041 79 559 59 29;
47
48 gregor.john@h-ne.ch (may be published).
49
50
51
52

53 **Number of References:** 23, **Tables:** 2, **Figures:** 3, and **Appendix:** 0
54
55
56
57

58 **Word counts:** Abstract: 288; Text: 2916
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Keywords: Heart-failure, diuretics, urinary catheter, non-inferiority study, hospital readmission, mortality

For peer review only

ABSTRACT:

Objectives: Patients with acute congestive heart failure (HF) regularly undergo urinary catheterisation (UC) at hospital admission. Little evidence exists on the real benefit of using UC in patients treated by diuretics for HF. We aimed at exploring risks and clinical benefits of UC during inpatient diuretic therapy for acute congestive HF.

Design: retrospective, non-inferiority study.

Setting: Geneva University Hospitals' (HUG) Department of Medicine, a tertiary centre.


Participants and intervention: In a cohort of HF, patients catheterised within 24h of diuretic therapy (n=113) were compared with non-catheterised patients (n=346).

Primary and secondary outcome measures: The primary endpoint was the forty-eight hours weight loss after starting diuretic therapy. Secondary endpoints were the time needed to reach target weight, discontinuation of intravenous diuretics, and resolution of respiratory failure. Safety outcomes included the time to a first urinary tract infection UTI, first hospital readmission and death.

Results: Forty-eight hours weight loss was not statistically different between groups and the adjusted difference was below the non-inferiority boundary of 1kg (0.43 kg (95% CI: -0.03–0.88) in favour of UC, $p < 0.01$ for non-inferiority). UC was not associated with time to reaching target weight (adjusted HR 1.0; 95%CI: 0.7–1.5), discontinuation of intravenous diuretics (aHR 0.9; 95%CI: 0.7–1.2), or resolution of respiratory failure (aHR 1.1; 95%CI: 0.5–2.4). UC increased the risk of urinary tract infection (aHR 2.5; 95%CI: 1.5–4.2). UC was not associated with hospital readmission (aHR 1.1, 95%CI: 0.8–1.4) or one-year mortality (aHR 1.4; 95%CI: 1.0–2.1).

1 **Conclusion:** The study demonstrated that UC within 24h of initiating diuretic treatment
2
3 had no impact on clinical improvement and increased risk of a urinary infection. This
4
5 evidence, therefore, argues against a systematic use of UC during a diuretic therapy
6
7 for HF.
8
9

10 11 12 13 14 **STRENGTHS AND LIMITATIONS OF THIS STUDY**

- 
- 17 • This is the first study to give an insight into the hypothetical clinically relevant
18 benefits of UC in the context of HF.
19
 - 20 • Using a register of prospective records and significant adjustments to potential
21 confounding factors further strengthened our findings.
22
 - 23 • The study's retrospective, observational approach only allowed us to
24 hypothesise that urinary catheters were placed for HF management or to
25 facilitate diuresis.
26
 - 27 • Since patients are usually not weighed in emergency rooms, we focused on the
28 weight change from days 1 to day 3. Thus, UC's impact during the first 24 h of
29 diuretic therapy was not assessed.
30
 - 31 • A randomised prospective design, with protocols to guide rapid diuretic
32 adaptation, would be better able to explore the UC's real potential among HF
33 patients. However, considering current evidence and risks, such a study may
34 never occur.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION:

Heart failure (HF) is a major, growing, worldwide public health concern, affecting 2% of the developed world's population.[¹] HF results in 1.7 million consultations and over 1 million hospitalisations yearly in the USA.[²] Since acute HF is the leading cause of hospitalisations in patients ≥ 65 years old, current demography will increase hospitalisation rates and health care costs.[^{1, 2}]

Diuretics are the mainstay treatments for volume overload.[^{3, 4}] Randomised studies of acute congestive HF have failed to associate either low or high initial doses of diuretics, or different modes of administration (continuous vs intermittent intravenous), with clinically significant differences in outcome.[⁵] Nevertheless, overly aggressive or insufficient treatments can result in acute kidney injury, electrolytic imbalance, low blood pressure, prolonged hospital length of stay (LOS) or early hospital readmission.[^{5, 6}] Assessing adequate response to diuretics, e.g. measuring diuresis, is therefore important and enables rapid treatment adjustment. This may be as or even more useful than how diuretics are initially administered.

Between one quarter [⁷] and one half of patients hospitalised for HF undergoes indwelling urinary catheter placement.[⁸] Indications for UC in this population include managing hypervolemia [^{8, 9}] or improving comfort during diuretic treatment.[¹⁰] By maximising the elimination of liquids while avoiding excessive losses, UC can have a positive impact on hospital LOS, readmission rates and even death. Although the benefits of UC remain uncertain, the risks of increased infectious and non-infectious complications are well known.[^{8, 11, 12}] A recent retrospective study of catheterised HF

1 patients showed no impact on LOS and an increased risk of infection.^[8] Little
2
3 evidence exists on UC's impact on clinically relevant improvements such as weight
4
5 loss, time to improvement of respiratory failure or time to discontinuation of
6
7 intravenous therapy. The present study aimed to determine the risks and clinical
8
9 benefits of UC among patients hospitalised for congestive HF.
10
11
12
13
14
15
16

17 **MATERIALS AND METHODS**

21 We conducted a retrospective, non-inferiority, cohort study using a pre-existing registry
22
23 of patients admitted to Geneva University Hospitals' (HUG) Department of Medicine
24
25 for acute HF.^[13, 14] Patients signed an informed consent at inclusion and were followed
26
27 for one year or until death. Data on weight, in-hospital diuretic use, UC and predefined
28
29 outcomes were obtained from paper medical charts, electronic medical records,
30
31 laboratory databases and Switzerland's national deaths registry. The institutional
32
33 review board approved the study and the need for informed consent to collect
34
35 retrospectively new information, was waived by the ethical committee (Comission
36
37 cantonale d'éthique de la recherche (CCER)). Reporting and analyses were performed
38
39 according to the Strengthening the Reporting of Observational Studies in Epidemiology
40
41 (STROBE) statement.
42
43
44
45
46
47
48
49

50 **STUDY POPULATION**

51
52
53 All patients ≥ 18 years old and included in the HF registry between 01.01.2006 and
54
55 01.01.2010 were eligible.^[13, 14] Patients were included in the registry if primarily
56
57 admitted for acute decompensated HF, with or without volume overload. Patients
58
59
60

1 without available paper medical charts for the index admission or who did not receive
2 diuretics during their first seven days of hospitalisation were excluded. We compared
3 patients who underwent UC within 24 h of diuretic therapy initiation with those not
4 catheterised.
5
6
7
8
9

10 11 12 13 14 15 **OUTCOMES**

16
17 The primary endpoint was the 48 h weight loss after starting diuretic therapy.
18 Secondary endpoints were persistent excess weight at 72 h and at one week, the time
19 needed to reach clinical improvement (reaching target weight (+/- 0.5 kg),
20 discontinuation of intravenous diuretics, oxygen supply and continuous positive airway
21 pressure (CPAP)), and hospital LOS.
22
23
24
25
26
27
28
29
30
31

32 Safety outcomes included the proportion of patients with a urinary tract infection (UTI),
33 initial diuretic treatment failure, worsening kidney function and episodes of low blood
34 pressure, and time to a first UTI, first hospital readmission and death. Initial treatment
35 failure was defined as a need for increased doses of diuretics, or a switch from oral to
36 intravenous diuretic therapy or from a bolus to a continuous intravenous diuretic
37 therapy two days or more after the initiation of diuretics. Diuretic dose increases before
38 that point were considered to be usual treatment adjustments.
39
40
41
42
43
44
45
46
47
48
49
50
51

52 53 **DATA COLLECTION**

54
55 Data extracted from medical charts included pre-admission diuretic use, micturition
56 volumes during diuretic therapy, weight at discharge and, for the first seven days, daily
57
58
59
60

1 information on the UC, weight, diuretics administration, clinical parameters, oxygen
2 supply and use of CPAP therapy.
3
4
5
6
7
8
9

10 Target weight was defined as the patient's weight at discharge or, when unavailable,
11 the lowest weight during hospitalisation that did not result in increased creatinaemia or
12 low blood pressure. We calculated excess weight by subtracting target weight from
13 weights measured during hospitalisation. Since patients are not always weighed on
14 admission day, 48 h weight loss was calculated between days 1 and 3 after starting
15 diuretic therapy (day 0). When weight on day 1 or on day 3, was missing, we took
16 double the mean daily weight loss calculated between day 0 to day 4.
17
18
19
20
21
22
23
24
25
26
27
28
29

30 Respiratory failure was defined as the need for oxygen supply or CPAP. We noted
31 episodes of low blood pressure (systolic pressure < 100 mmHg) and the need for
32 saline perfusion. Daily doses of torasemide were multiplied by four and doses of oral
33 furosemide were divided by two to convert daily diuretics use into an equivalent
34 intravenous furosemide dosage.
35
36
37
38
39
40
41
42
43
44
45

46 We obtained patients' habitual kidney function from their general practitioner.[¹⁴]
47 Kidney function at hospital admission and during the first week was extracted from the
48 laboratory database. When kidney function at admission was lower than its usual
49 value, acute kidney injury (AKI) was defined using the KDIGO classification, as
50 previously published by the same authors.[¹⁴] When kidney function decreased during
51 hospitalisation compared to admission values, it was defined as worsening kidney
52 function and scored according to the KDIGO classification.[¹⁴]
53
54
55
56
57
58
59
60

1
2
3
4 Comorbidity burdens were summarised using Charlson index, calculated using the
5 CIM-10 codes from electronic medical charts.^[15] HF types were stratified into
6
7 intermediate or reduced left ventricular ejection fraction (LVEF < 49%), preserved
8
9 LVEF (LVEF > 50%) and unknown LVEF.
10
11
12
13
14
15
16

17 We extracted urinary and blood culture information from the microbiology laboratory
18
19 database for each febrile episode during hospitalisation. A diagnosis of UTI was
20
21 defined as bacterial growth of $10E^3$ colony-forming units in a urine sample plus the
22
23 corresponding symptoms of a UTI.
24
25
26
27
28
29

30 Information on death was obtained from Switzerland's national deaths registry and
31
32 Geneva University Hospitals' (the only public hospital in the canton) electronic
33
34 databases. We reviewed charts for hospital LOS, place of discharge (home vs
35
36 rehabilitation centre or care home), and all-cause and HF-related hospital
37
38 readmissions within one year.
39
40
41
42

43 **PATIENT AND PUBLIC INVOLVEMENT**

44
45 Patients were not involved in the study design or conduct.
46
47

48 **STATISTICS**

49
50
51 For our analyses, timings (day 0) were set from the first day of diuretic use, which could
52
53 differ from the hospital admission day.
54
55
56

57 *Primary analysis and weight evolution*

58
59
60

1 Weight loss analyses during diuretic treatment were restricted to patients with volume
2 overload (excess weight at diuretic therapy). The primary analysis used a linear
3 regression model, where the 48 h weight loss was the dependent variable and UC was
4 the independent variable. The model was adjusted for age (continuous), sex (binary),
5 Charlson index score (continuous), pre-admission diuretic dose (continuous), HF type
6 (categorical), admission heart rate and blood pressure (continuous), respiratory failure
7 (binary), weight excess at diuretic therapy (continuous), first diuretic dose (continuous),
8 use of continuous intravenous diuretics (binary), AKI (categorical) and admission
9 through the emergency room (binary). Adjustment factors were chosen based on
10 clinical expertise. To reach non-inferiority, the upper confidence interval of a between-
11 group difference had to be less than 1 kg (in favour of UC). The 1 kg boundary was
12 arbitrarily chosen as a clinically relevant threshold. Unilateral T-test served to test non-
13 inferiority.

14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32 We performed three sensitivity analyses for the main outcome. Firstly, multiple
33 imputation method was used to replace missing values. Missing data, which were all
34 5% or less, were inspected to ensure that the missing at random assumption was
35 reasonable. Imputation involved all baseline responders and utilised the variables in
36 the adjusted models. Missing data were imputed using chained equations. Twenty
37 imputed datasets were generated and parameter estimates were combined using
38 Rubin's rules. The second sensitivity analysis excluded patients with urinary retention.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
The third matched catheterised patients 1:1 to non-catheterised patients according to
sex and the closest value (< 10%) of a propensity score. The score included all the
variables mentioned above except sex. A paired t-test was used to test mean
differences.

1 We used linear regression, adjusted for confounders, to explore associations between
2 UC and persistent weight excess at 72 h and one week. We also tested the interaction
3 between UC and time in a mixed-effects model adjusted for the factors mentioned
4 above. A random intercept for each patient accounted for repeated measures across
5 days. The mean expected excess weights of patients with and without UC was
6 calculated assuming mean values for continuous predictors and a proportion of
7 positive categorical predictors similar to the study sample.
8
9
10
11
12
13
14
15
16
17
18
19
20

21 *Clinical improvements, safety outcomes and other analyses*

22
23
24 The unadjusted impact of UC on time-dependent outcomes was analysed using
25 Kaplan–Meier survival analysis and an unweighted, two-sided, log-rank test to
26 compare groups. Analysis of target weight was restricted to patients with volume
27 overload. Analyses of intravenous diuretics, oxygen supply and CPAP were restricted
28 to patients receiving those therapies. Multivariate Cox models were adjusted for age,
29 sex and Charlson comorbidity index score. For target weight and the time needed to
30 discontinue intravenous diuretics, Cox models were further adjusted for all the
31 confounding factors in the primary analysis. The proportional hazards assumption was
32 verified using Schoenfeld residuals and a visual inspection of the log-minus-log plots.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

48 The association between UC and LOS was tested using a linear regression model
49 adjusted for confounding factors and in which LOS was log-transformed to correct for
50 skewed data. Logistic regression was used to adjust binary outcomes for
51 confounders. Comparisons of characteristics between groups were performed using
52 the chi-squared test or Fisher's exact test, where appropriate, for categorical
53 variables. The Mann–Whitney test was used for continuous variables as these were
54
55
56
57
58
59
60

1 not normally distributed. Except for the primary outcomes, all analyses were two-
2 sided, with a significance level set at 5%. All analyses were performed using STATA,
3
4 version 12.0, and R statistical software, Version 4.0.0.[¹⁶]
5
6
7
8
9
10
11

12 RESULTS

13
14
15
16 Of 640 potential participants in the HF register, 174 had no available paper medical
17 chart and 7 had had no diuretic therapy within the first 7 days, leaving a cohort of 459
18 patients of whom 113 underwent UC within the first 24 h (24.6%). Only four of these
19 patients had documented urinary retention. Catheterised patients were older, more
20 often women, more frequently experienced respiratory failure or AKI, and received
21 higher initial diuretic doses (**Table 1**). Urinary catheters were placed for a median of 4
22 days (IQR: 2–8). Diuresis was recorded more often among patients with UC (58.0%)
23 than patients without (41.2%, $p < 0.01$).
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38

39 EXCESS WEIGHT UNDER DIURETIC THERAPY

40
41
42 At diuretic therapy initiation, 342 patients carried excess weight and were included in
43 the primary analysis. In adjusted linear regressions, being catheterised was not
44 associated with significantly greater 48 h weight loss than not being catheterised
45 (0.43 Kg in favour of UC (95% CI: -0.03–0.88)). The upper confidence interval of
46 between-group difference was below the non-inferiority boundary of 1 kg ($p < 0.01$ for
47 non-inferiority).
48
49
50
51
52
53
54
55

56
57 In sensitivity analysis, the results were in line with the primary analysis. The difference
58 in 48 h weight loss, after multiple imputation for missing values, was 0.33 kg (95% CI:
59
60

1 -0.1–0.76; $p < 0.01$ for non-inferiority). Excluding patients with urinary retention ($n = 4$)
2
3 did not change the results (data not shown). In the last sensitivity analysis, 64 patients
4
5 with UC were matched with 64 patients without one (none had urinary retention). The
6
7 difference in weight loss was 0.29 kg (95% CI: -0.3–0.88; $p < 0.01$ for non-inferiority).
8
9

10
11
12
13
14
15 Patients with UC did not have a statistically lower persistent excess weight at 72 h: the
16
17 difference was 0.27 kg (95% CI: -0.52–1.1; $p = 0.50$) in unadjusted and 0.24 kg
18
19 (95% CI: -0.17–0.64; $p < 0.001$ for non-inferiority) in adjusted linear regression. At one
20
21 week, the excess weight difference between patients with and without UC was -0.09 kg
22
23 (95% CI: -1.0–0.8; $p = 0.84$) in unadjusted and -0.14 kg (95% CI: -0.89–0.60; $p = 0.01$
24
25 for non-inferiority) in adjusted linear regression. Similarly, there was no statistically
26
27 significant interaction between UC and daily excess weight changes in the mixed-
28
29 effects model ($p = 0.55$; **Figure 1**).
30
31
32
33
34
35
36
37

38 **CLINICAL IMPROVEMENT**

39
40
41 Time to reach target weight and time needed to discontinue CPAP were not statistically
42
43 different between patients with and without UC in both unadjusted and adjusted
44
45 analysis (**Figure 2, Table 2**). UC tended to be associated with a longer time to
46
47 discontinuation of an intravenous diuretic or discontinuation of oxygen supply (**Figure**
48
49 **2**), but the associations disappeared after adjustment for confounders (**Table 2**).
50
51
52
53
54
55
56
57
58
59
60

1 The median hospital LOS was identical for patients with and without UC (12 days, IQR:
2 9–18). However, fewer UC patients were discharged directly home from hospital
3 (57.3% vs 73.7%; adjusted OR 0.6 (95% CI: 0.3–0.9; $p < 0.01$)).
4
5
6
7
8
9
10
11

12 SAFETY OUTCOMES

13
14
15 The proportions of initial treatment failures, low blood pressure episodes and patients
16 with worsening kidney function were not statistically different between groups (**Table**
17 **2**).
18
19
20
21
22
23
24
25
26

27 All-cause and HF-related readmissions were not statistically different between patients
28 with and without UC (**Table 2** and **Figure 3**). Half the patients with UC and one third
29 without UC were dead at one year. The difference was not statistically significant after
30 adjustment (**Table 2**).
31
32
33
34
35
36
37
38
39

40 UC patients were at a higher risk of suffering from a UTI, and this association persisted
41 in adjusted analyses (**Table 2** and **Figure 3**). Multiple UTIs occurred in 9 UC patients
42 (8.0%) and in 5 patients without UC (1.2%, $p < 0.01$). Patients with a UTI had a longer
43 hospital LOS (15 days (IQR: 10–21) vs 11 days (IQR: 8–17), $p < 0.001$) and an
44 increased one-year mortality rate (52.5% vs 34.0%, adjusted HR 1.5; 95% CI: 1.1–2.3;
45 $p = 0.038$).
46
47
48
49
50
51
52
53
54
55
56
57

58 DISCUSSION AND CONCLUSION

1 Among patients admitted to medical wards for acute HF, initial weight loss was not
2
3 different for the strategy of abstaining from UC compared to UC placement within the
4
5 first 24 h. Besides, UC had no impact on clinical improvement such as the time needed
6
7 to reach target weight, discontinue intravenous diuretics or improve respiratory failure,
8
9 and hospital LOS. Furthermore, UC did not prevent excessive diuresis resulting in low
10
11 blood pressure episodes or worsening kidney function. However, UC was associated
12
13 with a higher risk of a UTI.
14
15
16
17
18
19
20

21 There are few appropriate indications for UC,^[11] and 7% to 50% of UCs are done
22
23 outside these indications.^[17, 18] Rates of UC subsequent to HF vary greatly and could
24
25 be very high. In one study, more than half of haemodynamically stable patients
26
27 underwent UC.^[8] The rationale for UC in HF is weak yet somehow based on beliefs
28
29 that it facilitates urine elimination and increases comfort by decreasing toilet visits.
30
31 However, there is good evidence that UC does not increase the comfort of patients
32
33 undergoing diuretic therapy, even at high dosages.^[10] Most guidelines on UC good
34
35 practice do not list HF as a standard indication.^[19] Through their *Choosing Wisely*
36
37 campaigns, Swiss and American authorities recommend avoiding in-dwelling UC for
38
39 urine output monitoring in stable patients who can void or for patient or staff
40
41 convenience.^[20, 21] Indication lists, authorities' recommendations and financial
42
43 penalties have reduced the overall inappropriate use of UC.^[11] An American study
44
45 showed that the proportion of UC among HF patients decreased by 8% between 2009
46
47 and 2014.^[7]
48
49
50
51
52
53
54
55
56
57
58
59
60

1 Catheter-associated UTIs (CAUTIs) are the second most common infections
2 associated with patients hospitalised for HF after *Clostridium*-related infections.[²²]
3
4 Previous reports among HF patients found associations between CAUTI and increased
5
6 risks of discharge to a skilled care facility, longer hospital LOS, higher total hospital
7
8 costs and in-hospital mortality.[^{8, 22}] Condom catheters are a better option when
9
10 diuresis affects older patients with a disability: they lead to fewer complications,[²³] are
11
12 more comfortable and are less painful than UC.[¹⁰]
13
14
15
16
17
18
19
20
21

22 The present study is the first to give an insight into the hypothetical clinically relevant
23 benefits of UC in the context of HF. Using a register of prospective records and
24 significant adjustments to potential confounding factors (some collected
25 retrospectively) further strengthened our findings. However, the study has limitations.
26
27 Firstly, the study's retrospective, observational approach only allowed us to
28 hypothesise that urinary catheters were placed for HF management or to facilitate
29 diuresis. To minimise these issues, we only selected UCs which occurred in the first
30 24 h of diuretic therapy. Secondly, since patients are usually not weighed in emergency
31 rooms, we focused on the weight change from days 1 to day 3. Thus, UC's impact
32 during the first 24 h of diuretic therapy was not assessed. A randomised prospective
33 design, with protocols to guide rapid diuretic adaptation, would be better able to explore
34 the UC's real potential among HF patients. However, considering current evidence and
35 risks, such a study may never occur. It is of note that records of the amount of urine
36 passed were only available for half of the patients, with or without UC. Thus, checking
37 for adequate diuresis after treatment with diuretics might be a simpler, safer
38 recommendation than UC for improved HF management. Finally, some medical charts
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 could not be retrieved, but their unavailability was random and unrelated to their UC
2 status or outcomes. Thus, there is little risk that unavailable charts biased the results.
3
4

5
6
7
8
9 UC within 24 h of diuretic therapy initiation had no proven impact on the clinically
10 relevant outcomes of time to reach target weight, time to resolve respiratory failure and
11 hospital LOS. The lack of benefits and the increased risk of a UTI preclude systematic
12 UC for the management of HF.
13
14
15
16
17

21 DATA AVAILABILITY

22
23
24
25 The database, variable explanation, and Stata do-file (in Word format) are available at
26 request to gregor.john@h-ne.ch.
27
28
29
30
31
32

34 REFERENCES

- 35
36
37 1. Savarese, G., Lund, L. H. Global Public Health Burden of Heart Failure. *Card Fail Rev.* **3**, 7-11
38 (2017).
39
40
41
42 2. Benjamin, E. J. *et al.* Heart Disease and Stroke Statistics-2019 Update: A Report From the
43 American Heart Association. *Circulation.* **139**, e56-e528 (2019).
44
45
46
47 3. Jessup, M. *et al.* 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and
48 Management of Heart Failure in Adults: a report of the American College of Cardiology
49 Foundation/American Heart Association Task Force on Practice Guidelines: developed
50 in collaboration with the International Society for Heart and Lung Transplantation.
51
52
53
54
55
56
57
58
59
60
Circulation. **119**, 1977-2016 (2009).

- 1 4. McMurray, J. J. *et al.* ESC Guidelines for the diagnosis and treatment of acute and chronic
2
3 heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and
4
5 Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in
6
7 collaboration with the Heart Failure Association (HFA) of the ESC. *Eur Heart J.* **33**, 1787-
8
9 847 (2012).
- 10
11
12
13 5. Felker, G. M. *et al.* Diuretic strategies in patients with acute decompensated heart failure.
14
15 *N Engl J Med.* **364**, 797-805 (2011).
- 16
17
18 6. Felker, G. M., O'Connor, C. M., Braunwald, E. Loop diuretics in acute decompensated heart
19
20 failure: necessary? Evil? A necessary evil? *Circ Heart Fail.* **2**, 56-62 (2009).
- 21
22
23 7. Metersky, M. L. *et al.* National trends in the frequency of bladder catheterization and
24
25 physician-diagnosed catheter-associated urinary tract infections: Results from the
26
27 Medicare Patient Safety Monitoring System. *Am J Infect Control.* **45**, 901-04 (2017).
- 28
29
30 8. Jang, A. Y. *et al.* Routine Indwelling Urethral Catheterization in Acute Heart Failure Patients
31
32 Is Associated With Increased Urinary Tract Complications Without Improved Heart
33
34 Failure Outcomes. *Circ J.* **82**, 1632-39 (2018).
- 35
36
37 9. Aoki, T. Appropriate Use of Urinary Catheter in Acute Heart Failure Patients. *Circ J.* **82**, 1505-
38
39 06 (2018).
- 40
41
42 10. Saint, S. *et al.* Condom versus indwelling urinary catheters: a randomized trial. *J Am Geriatr*
43
44 *Soc.* **54**, 1055-61 (2006).
- 45
46
47 11. Meddings, J. *et al.* Reducing unnecessary urinary catheter use and other strategies to
48
49 prevent catheter-associated urinary tract infection: an integrative review. *BMJ Qual*
50
51 *Saf.* **23**, 277-89 (2014).
- 52
53
54 12. Hollingsworth, J. M. *et al.* Determining the noninfectious complications of indwelling
55
56 urethral catheters: a systematic review and meta-analysis. *Ann Intern Med.* **159**, 401-
57
58 10 (2013).
- 59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
13. Garin, N. *et al.* Inclusion into a heart failure critical pathway reduces the risk of death or readmission after hospital discharge. *Eur J Intern Med.* **23**, 760-4 (2012).
14. Berra, G. *et al.* Outcome in acute heart failure: prognostic value of acute kidney injury and worsening renal function. *J Card Fail.* **21**, 382-90 (2015).
15. Sundararajan, V. *et al.* New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. *J Clin Epidemiol.* **57**, 1288-94 (2004).
16. R Core Team (2017). R: A language and environment for statistical computing. [program], 2019. R Foundation for Statistical Computing, Vienna, Austria. URL <https://www.R-project.org/>.
17. Saint, S. *et al.* Are physicians aware of which of their patients have indwelling urinary catheters? *Am J Med.* **109**, 476-80 (2000).
18. Gokula, R. R., Hickner, J. A., Smith, M. A. Inappropriate use of urinary catheters in elderly patients at a midwestern community teaching hospital. *Am J Infect Control.* **32**, 196-9 (2004).
19. Centers for Disease Control and Prevention. Examples of Appropriate Indications for Indwelling Urethral Catheter Use. URL: <https://www.cdc.gov/infectioncontrol/guidelines/cauti/recommendations.html> (last access: 09.04.2020)
20. Physicians ACoE. Choosing Wisely, 2013. URL: <https://www.choosingwisely.org/societies/american-college-of-emergency-physicians/> (last access: 09.04.2020)
21. Générale SSdmi. Choosing Wisely, 2016. URL: <https://www.smartermedicine.ch/fr/liste-top-5/infektiologie.html#c15766> (last access: 09.04.2020)
22. Miller, P. E. *et al.* National Trends in Healthcare-Associated Infections for Five Common Cardiovascular Conditions. *Am J Cardiol.* **124**, 1140-48 (2019).

1 23. Saint, S. *et al.* Condom Catheters versus Indwelling Urethral Catheters in Men: A
2
3
4 Prospective, Observational Study. *J Hosp Med.* **14**, E1-E4 (2019).
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

ACKNOWLEDGEMENTS

We gratefully acknowledge Elise Dupuis for her help with the statistical analysis.

FUNDING

The study received a grant from Geneva University Hospitals (grant: PRD 1-2017-I).

AUTHORS STATEMENT

G.J.: planned the study (protocol), performed the analyses and wrote the manuscript.

S.C.: planned the study (protocol) and reviewed and approved the final manuscript.

D.C.: planned the study (protocol) and reviewed and approved the final manuscript.

N.G.: planned the study (protocol) and reviewed and approved the final manuscript.

J.S.: planned the study (protocol), performed the analyses, and reviewed and approved the final manuscript.

M.A.: collected the data and reviewed and approved the final manuscript.

G.B.: collected the data and reviewed and approved the final manuscript.

CONFLICT OF INTEREST STATEMENT

The authors declare no competing interests.

ABBREVIATIONS

AKI: acute kidney injury

CI: confidence interval

CPAP: continuous positive airway pressure HF: heart failure

HR: hazard ratio

HUG: Geneva University Hospitals

KDIGO: Kidney Disease: Improving Global Outcomes

LVEF: left ventricular ejection fraction

OR: odds ratio UC: urinary catheterisation

UTI: urinary tract infection

1
2
3
4 **Figure 1:** Predicted excess weight for patients with (black line) and without (green line) urinary
5 catheterisation (UC). Mean expected excess weights and their confidence intervals were
6 calculated using an adjusted mixed-effects model assuming mean values for continuous
7 predictors and a proportion of positive categorical predictors similar to the study sample. UC
8 had no statistical effect on excess weight evolution over time (p for interaction = 0.55).
9
10
11
12
13
14
15
16
17
18
19
20

21 **Figure 2:** Time to reach clinical improvement for patients with urinary catheterisation (black
22 line) and controls (green line): (A) time to reach target weight; (B) time to discontinuation of
23 intravenous diuretics; (C) time to discontinuation of continuous positive airway pressure
24 therapy; and (D) time to discontinuation of oxygen supply.
25
26
27
28
29
30
31
32
33
34
35
36


37 **Figure 3:** Time to reach unfavourable outcomes for patients with urinary catheterisation (black
38 line) and controls (green line): (A) time to first urinary tract infection; (B) time to first all-cause
39 hospital readmission; (C) time to first heart failure-related readmission; and (D) time to death.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1: Characteristics of participants with and without urinary catheterisation (UC). Only UC within 24 h of diuretic therapy initiation was considered. Values are numbers (percentage) unless otherwise stated.

Characteristic	Cohort (N = 459)	With UC (N = 113)	Without UC N = 346)	P value
Age (y), median (IQR)	81 (73–86)	83.5 (76–89)	80 (71–85)	< 0.001
Male	248 (55.2%)	52 (47.3%)	196 (57.8%)	0.053
Admitted through ER	398 (86.7%)	97 (85.8%)	301 (87.0%)	0.754
Night-time admission (19h00–07h00)	169 (36.8%)	37 (32.7%)	132 (38.1%)	0.301
Current smoker	79 (18.0%)	18 (17.3%)	61 (18.1%)	0.844*
High blood pressure	331 (73.7%)	83 (73.7%)	248 (73.2%)	0.709
Diabetes	135 (30.1%)	34 (30.9%)	101 (29.8%)	0.812
Myocardial infarct	27 (6.1%)	6 (5.5%)	21 (6.3%)	0.762*
Stroke	52 (11.8%)	18 (16.1%)	34 (10.2%)	0.076*
Peripheral vascular disease	76 (17.2%)	23 (21.1%)	53 (15.9%)	0.242*
Dementia	30 (6.8%)	9 (8.3%)	21 (6.3%)	0.482*
COPD	66 (14.7%)	16 (14.5%)	50 (14.7%)	0.958*
Oncological disease	32 (7.2%)	8 (7.3%)	24 (7.2%)	0.963*
Liver disease	24 (5.4%)	7 (6.4%)	17 (5.1%)	0.598*
CKD				
II	174 (38.7%)	39 (35.4%)	135 (39.2%)	0.380
III	154 (34.4%)	40 (36.4%)	114 (33.6%)	
IV	22 (4.9%)	6 (5.5%)	16 (4.7%)	
V	2 (0.5%)	0	2 (0.6%)	
Charlson comorbidity index, median (IQR)	3 (1–4)	3 (2–4)	3 (1–4)	0.115
Pre-admission medication				
ACE/ARB	290 (64.6%)	65 (59.1%)	225 (66.4%)	0.165
Beta-blocker	204 (45.4%)	49 (44.5%)	155 (45.7%)	0.829
Aldosterone inhibitor	62 (13.8%)	14 (12.7%)	48 (14.2%)	0.753*
Diuretics	239 (52.1%)	66 (58.4%)	173 (50.0%)	0.120
Admission characteristics				
Heart rate (beat/min), median (IQR)	81 (70–94)	82.5 (70–91)	80 (69.5–95)	0.785
Mean blood pressure (mmHg), median (IQR)	90 (80–100)	88.3 (78.3–100)	90 (80.3–100)	0.162
AKI				
I	143 (31.5%)	46 (41.8%)	97 (28.6%)	0.002*
II	24 (5.3%)	9 (8.2%)	15 (4.4%)	
III	5 (1.1%)	3 (2.7%)	2 (0.6%)	
Respiratory failure:	371 (80.8%)	105 (92.9%)	266 (76.9%)	< 0.001*
- Needs oxygen supply	365 (79.5%)	104 (92.0%)	261 (75.4%)	
- CPAP	75 (16.3%)	27 (23.9%)	48 (13.9%)	
Volume overload	342 (74.5%)	86 (76.1%)	256 (74.0%)	0.654
- Target weight (kg), median (IQR)	69.2 (58.1–80.8)	70 (58–81.4)	68.7 (58.6–80.5)	
Intravenous therapy	431 (93.9%)	108 (95.6%)	323 (93.4%)	0.391*
Continuous intravenous diuretic therapy	42 (9.2%)	15 (13.4%)	27 (7.8%)	0.076*
Initial diuretic doses (mg), median (IQR)	40 (30–80)	60 (40–90)	40 (20–60)	< 0.001
* Fischer test				
ACE, angiotensin-converting-enzyme inhibitor; AKI, acute kidney injury; ARB, angiotensin receptor blockers; CKD, chronic kidney disease by CKD-EPI classification; COPD, chronic obstructive pulmonary disease; CPAP, continuous positive airway pressure therapy; ER, emergency room; UC: urinary catheterisation				


Table 2: Clinical improvements and adverse outcomes with and without urinary catheterisation. Values are numbers unless otherwise stated.

Time to clinical improvement	With UC	Without UC	HR	Adjusted HR
Time to target weight (d), median (IQR)	6 (3–7)	6 (3–7)	1.1 (0.8–1.5)	1.0 (0.7–1.5)
Time to switch/discontinuation of intravenous diuretics (d), median (IQR)	4 (2–8)	3 (1–6)	0.8 (0.7–1.0)	0.9 (0.7–1.2)
Time to discontinuation of CPAP (d), median (IQR)	4 (2–6)	4 (2–5)	1.2 (0.7–2.2)	1.1 (0.5–2.4)
Time to discontinuation of oxygen supply (d), median (IQR)	4 (2–8)	3 (1–7)	0.8 (0.6–1.0)	0.9 (0.7–1.2)
Time to adverse events	With UC	Without UC	HR	Adjusted HR
Urinary tract infection, n (%)	37 (32.7%)	46 (13.3%)	2.9 (1.8–4.8)*	2.5 (1.5–4.2)*
One-year all-cause hospital readmission, n (%)	56 (50.9%)	193 (56.9%)	1.1 (0.8–1.4)	1.1 (0.8–1.4)
One-year heart failure-related hospital readmission, n (%)	28 (25.5%)	91 (26.8%)	1.1 (0.7–1.7)	1.1 (0.7–1.7)
One-year mortality, n (%)	51 (50.0%)	101 (33.4%)	1.7 (1.2–2.4)*	1.4 (1.0–2.1)
Other secondary outcomes	With UC	Without UC	OR	Adjusted OR
Initial treatment failure	23 (26.7%)	78 (30.5%)	0.8 (0.5–1.4)	0.8 (0.4–1.4)
Low blood pressure episode	49 (43.7%)	154 (44.6%)	1.0 (0.6–1.5)	1.1 (0.7–1.7)
- Need of saline perfusion	24/49 (49.0)	67/154 (43.5)		
Worsening of renal function				
0	82 (74.6%)	260 (76.7%)	1.1 (0.7–1.8)†	1.1 (0.7–1.8)†
1	27 (24.6%)	73 (21.5%)		
2	1 (-)	6 (1.8%)		
* <i>p</i> value < 0.05; † OR of changing to a worse category				
CPAP, continuous positive airway pressure therapy; UC, urinary catheterisation				




Predicted excess weight (kg) over time (days) for patients with (black line) and without (green line) urinary catheterisation (UC). Mean expected excess weights and their confidence intervals were calculated using an adjusted mixed-effects model assuming mean values for continuous predictors and a proportion of positive categorical predictors similar to the study sample. UC had no statistical effect on excess weight evolution over time (p for interaction = 0.55).

296x209mm (150 x 150 DPI)



Time to reach clinical improvement for patients with urinary catheterisation (black line) and controls (green line): (A) time to reach target weight; (B) time to discontinuation of intravenous diuretics; (C) time to discontinuation of continuous positive airway pressure supply; and (D) time to discontinuation of oxygen supply.

244x178mm (72 x 72 DPI)



Time to reach unfavourable outcomes for patients with urinary catheterisation (black line) and controls (green line): (A) time to first urinary tract infection; (B) time to first all-cause hospital readmission; (C) time to first heart failure-related readmission; and (D) time to death.

244x178mm (72 x 72 DPI)

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No.	Recommendation	Page No.	Relevant text from manuscript
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1, 3	
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3,4	
Introduction				
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5	
Objectives	3	State specific objectives, including any prespecified hypotheses	5-6	
Methods				
Study design	4	Present key elements of study design early in the paper	6	
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6-7	
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	6-7	
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	10-11	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	9	
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	9	
Bias	9	Describe any efforts to address potential sources of bias	10	
Study size	10	Explain how the study size was arrived at	NA	

Continued on next page

Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	10
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	9-11
		(b) Describe any methods used to examine subgroups and interactions	NA
		(c) Explain how missing data were addressed	6
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed	10-11
		<i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	10
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	12-14, table 1-2
		(b) Give reasons for non-participation at each stage	
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Table 1
		(b) Indicate number of participants with missing data for each variable of interest	12
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	Figure2-3
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	Figure2-3
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	NA
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Table2
		(b) Report category boundaries when continuous variables were categorized	
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	

Continued on next page

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	12
Discussion			
Key results	18	Summarise key results with reference to study objectives	14
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	16
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	16
Generalisability	21	Discuss the generalisability (external validity) of the study results	16
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	16-17

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Risks and benefits of urinary catheterisation during inpatient diuretic therapy for acute heart failure: A retrospective, non-inferiority, cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-053632.R1
Article Type:	Original research
Date Submitted by the Author:	02-Dec-2021
Complete List of Authors:	John, Gregor; Hôpitaux Universitaires Genève, Department of Internal Medicine; Université de Genève, Department of Medicine Arcens, Marc; Hôpitaux Universitaires Genève, Department of Medicine Berra, Gregory; Hôpitaux Universitaires Genève, Department of Medicine Garin, Nicolas; Hôpitaux Universitaires Genève, Department of Medicine; Université de Genève Carballo, David ; Université de Genève; Hôpitaux Universitaires Genève, Department of Medicine Carballo, Sebastian; Hôpitaux Universitaires Genève, Department of Medicine; Université de Genève Stirnemann, Jerome; Hôpitaux Universitaires Genève, Department of Medicine; Université de Genève
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Medical management, Infectious diseases, Geriatric medicine, Evidence based practice
Keywords:	Heart failure < CARDIOLOGY, Urinary tract infections < UROLOGY, Health & safety < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1 **Title:** Risks and benefits of urinary catheterisation during inpatient
2
3
4 diuretic therapy for acute heart failure: A retrospective, non-inferiority,
5
6 cohort study
7
8
9

10 **Running headline:** urinary catheterisation in acute heart failure.
11
12
13

14 Gregor John^{1,2,3*}, Marc Arcens², Gregory Berra², Nicolas Garin^{2,3}, David Carballo^{3,4},
15
16 Sebastian Carballo^{2,3}, Jérôme Stirnemann^{2,3}.
17
18
19
20

21 1. Department of Internal Medicine, Neuchâtel Hospital Network, Rue de la Maladière
22
23 45, CH-2000 Neuchâtel, Switzerland
24
25

26 2. Department of Medicine, Geneva University Hospitals (HUG), Gabrielle-Perret-
27
28 Gentil 4, CH-1205 Geneva, Switzerland; Fax: 0041 32 967 27 29, Phone: 0041 79
29
30 559 59 29; gregor.john@h-ne.ch (may be published).
31
32

33 3. Geneva university, Michel-Servet 1, 1211 Genève 4, Switzerland.
34

35 4. Cardiology Service, Department of Medicine, Geneva University Hospitals (HUG),
36
37 Gabrielle-Perret-Gentil 4, CH-1205 Geneva, david.carballo@hcuge.ch
38
39
40
41

42 ***Gregor John^{1,2,3*}**, PD, MD (correspondence and requests for reprints); Department
43
44 of Internal Medicine, Neuchâtel Hospital Network, Rue de la Maladière 45, CH-2000
45
46 Neuchâtel, Switzerland. Fax: 0041 32 967 27 29, Phone: 0041 79 559 59 29;
47
48 gregor.john@h-ne.ch (may be published).
49
50
51
52

53 **Number of References:** 23, **Tables:** 2, **Figures:** 3, and **Appendix:** 0
54
55

56 **Word counts:** Abstract: 295; Text: 3066
57

58 **Keywords:** Heart-failure, diuretics, urinary catheter, non-inferiority study, hospital
59 readmission, mortality
60

ABSTRACT:

Objectives: Patients with acute congestive heart failure (HF) regularly undergo urinary catheterisation (UC) at hospital admission. Little evidence exists on the real benefit of using UC in patients treated by diuretics for HF. We aimed at exploring risks and clinical benefits of UC during inpatient diuretic therapy for acute congestive HF.

Design: retrospective, non-inferiority study.

Setting: Geneva University Hospitals' (HUG) Department of Medicine, a tertiary centre.

Participants: In a cohort of HF, patients catheterised within 24h of diuretic therapy (n=113) were compared with non-catheterised patients (n=346).

Primary and secondary outcome measures: The primary endpoint was the forty-eight hours weight loss after starting diuretic therapy. Secondary endpoints were the time needed to reach target weight, discontinuation of intravenous diuretics, and resolution of respiratory failure. Safety outcomes included the time to a first urinary tract infection UTI, first hospital readmission and death.

Results: Forty-eight hours weight loss was not statistically different between groups and the adjusted difference was below the non-inferiority boundary of 1kg (0.43 kg (95% CI: -0.03–0.88) in favour of UC, $p < 0.01$ for non-inferiority). UC was not associated with time to reaching target weight (adjusted HR 1.0; 95%CI: 0.7–1.5), discontinuation of intravenous diuretics (aHR 0.9; 95%CI: 0.7–1.2), or resolution of respiratory failure (aHR 1.1; 95%CI: 0.5–2.4). UC increased the risk of urinary tract infection (aHR 2.5; 95%CI: 1.5–4.2). UC was not associated with hospital readmission (aHR 1.1, 95%CI: 0.8–1.4) or one-year mortality (aHR 1.4; 95%CI: 1.0–2.1).

1 **Conclusion:** In this retrospective study, with no obvious hourly diuresis-based diuretic
2 adjustment strategy, UC insertion within 24h of initiating diuretic treatment had no
3 impact on clinical improvement but increased risk of a urinary infection. This evidence,
4 therefore, argues against a systematic use of UC during a diuretic therapy for HF.
5
6
7
8
9

10 11 12 13 14 **‘STRENGTHS AND LIMITATIONS OF THIS STUDY’**

- 15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- The present study is the first to give an insight into the hypothetical clinically relevant benefits of UC in the context of HF.
 - The preceded the advent of sacubitril or SGLT2 inhibitors therapy. Nevertheless, in 2021, updated ESC guidelines did not evolve regarding diuretics or the relevance of UC insertion for the management of acute decompensate HF. .
 - The study’s retrospective, observational approach only allowed us to hypothesise that urinary catheters were placed for HF management or to facilitate diuresis.
 - Since patients are usually not weighed in emergency rooms, we focused on the weight change from days 1 to day 3. Thus, UC’s impact during the first 24 h of diuretic therapy was not assessed.
 - A randomised prospective design, with protocols to guide rapid diuretic adaptation, would be better able to explore the UC’s real potential among HF patients. However, considering current evidence and risks, such a study may never occur.

INTRODUCTION:

Heart failure (HF) is a major, growing, worldwide public health concern, affecting 2% of the developed world's population.[¹] HF results in 1.7 million consultations and over 1 million hospitalisations yearly in the USA.[²] Since acute HF is the leading cause of hospitalisations in patients ≥ 65 years old, current demography will increase hospitalisation rates and health care costs.[^{1, 2}]

Diuretics are the mainstay treatments for volume overload.[^{3, 4}] Randomised studies of acute congestive HF have failed to associate either low or high initial doses of diuretics, or different modes of administration (continuous vs intermittent intravenous), with clinically significant differences in outcome.[⁵] Nevertheless, overly aggressive or insufficient treatments can result in acute kidney injury, electrolytic imbalance, low blood pressure, prolonged hospital length of stay (LOS) or early hospital readmission.[^{5, 6}] Assessing adequate response to diuretics, e.g. measuring diuresis, is therefore important and enables rapid treatment adjustment. This may be as or even more useful than how diuretics are initially administered.

Between one quarter [⁷] and one half of patients hospitalised for HF undergoes indwelling urinary catheter placement.[⁸] Indications for UC in this population include managing hypervolemia [^{8, 9}] or improving comfort during diuretic treatment.[¹⁰] By maximising the elimination of liquids while avoiding excessive losses, UC can have a positive impact on hospital LOS, readmission rates and even death. Although the benefits of UC remain uncertain, the risks of increased infectious and non-infectious complications are well known.[^{8, 11, 12}] A recent retrospective study of catheterised HF

1 patients showed no impact on LOS and an increased risk of infection.^[8] Little
2
3 evidence exists on UC's impact on clinically relevant improvements such as weight
4
5 loss, time to improvement of respiratory failure or time to discontinuation of
6
7 intravenous therapy. The present study aimed to determine the risks and clinical
8
9 benefits of UC among patients hospitalised for congestive HF.
10
11
12
13
14
15
16

17 **MATERIALS AND METHODS**

21 We conducted a retrospective, non-inferiority, cohort study using a pre-existing cohort
22
23 of patients admitted to Geneva University Hospitals' (HUG) Department of Medicine
24
25 for acute HF.^[13, 14] Patients were followed for one year or until death. Data on weight,
26
27 in-hospital diuretic use, UC and predefined outcomes were obtained from paper
28
29 medical charts, electronic medical records, laboratory databases and Switzerland's
30
31 national deaths registry. The institutional review board approved the study and the
32
33 need for informed consent to collect retrospectively information, was waived by the
34
35 ethical committee (Comission cantonale d'éthique de la recherche (CCER)). Reporting
36
37 and analyses were performed according to the Strengthening the Reporting of
38
39 Observational Studies in Epidemiology (STROBE) statement.
40
41
42
43
44
45
46
47

48 **STUDY POPULATION**

51 All patients ≥ 18 years old requiring hospital admission for a primary symptom of
52
53 dyspnoea and a diagnosis of acute decompensated HF between 01.01.2006 and
54
55 01.01.2010 were eligible.^[13, 14] Acute decompensated HF was diagnosed from
56
57 patients' clinical presentation, risk factors and treatment responsiveness or was
58
59
60

1 supported by structural or functional echocardiographic anomalies. Patients with final
2 diagnosis other than HF that explained their dyspnoea, with low NT-proBNP level
3 (<300ng/l), who were admitted to the intensive care unit, whose paper medical charts
4 for the index admission were available or who did not receive diuretics during their first
5 seven days of hospitalisation were excluded. We compared patients who underwent
6 UC insertion within 24 h of diuretic therapy initiation with those not catheterised.
7
8
9
10
11
12
13
14
15
16
17
18

19 **OUTCOMES**

20
21
22 The primary endpoint was the 48 h weight loss after starting diuretic therapy.
23 Secondary endpoints were persistent excess weight at 72 h and at one week, the time
24 needed to reach clinical improvement (reaching target weight (+/- 0.5 kg),
25 discontinuation of intravenous diuretics, oxygen supply and continuous positive airway
26 pressure (CPAP)), and hospital LOS.
27
28
29
30
31
32
33
34
35
36

37 Safety outcomes included the proportion of patients with a urinary tract infection (UTI),
38 initial diuretic treatment failure, worsening kidney function and episodes of low blood
39 pressure, and time to a first UTI, first hospital readmission and death. Initial treatment
40 failure was defined as a need for increased doses of diuretics, or a switch from oral to
41 intravenous diuretic therapy or from a bolus to a continuous intravenous diuretic
42 therapy two days or more after the initiation of diuretics. Diuretic dose increases before
43 that point were considered to be usual treatment adjustments.
44
45
46
47
48
49
50
51
52
53
54
55
56

57 **DATA COLLECTION**

1 Data extracted from medical charts included pre-admission diuretic use, micturition
2 volumes during diuretic therapy, weight at discharge and, for the first seven days, daily
3 information on the UC, weight, diuretics administration, clinical parameters, oxygen
4 supply and use of CPAP therapy.
5
6
7
8
9

10
11
12
13
14 Volume overload (hypervolaemia) was defined as excess weight at diuretic therapy.
15 We calculated excess weight by subtracting target weight from other weights
16 measured during hospitalisation. Target weight was defined as the patient's weight at
17 discharge or, when unavailable, the lowest weight during hospitalisation that did not
18 result in increased creatinaemia or low blood pressure. Since patients are not always
19 weighed on admission day, 48 h weight loss was calculated between days 1 and 3
20 after starting diuretic therapy (day 0). When weight on day 1 or on day 3, was missing,
21 we took double the mean daily weight loss calculated between day 0 to day 4.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36

37 Respiratory failure was defined as the need for oxygen supply or CPAP. We noted
38 episodes of low blood pressure (systolic pressure < 100 mmHg) and the need for
39 saline perfusion. Daily doses of torasemide were multiplied by two and doses of oral
40 furosemide were divided by two to convert daily diuretics use into an equivalent
41 intravenous furosemide dosage.^[15]
42
43
44
45
46
47
48
49
50
51
52

53 We obtained patients' habitual kidney function from their general practitioner.^[14]
54 Kidney function at hospital admission and during the first week was extracted from the
55 laboratory database. We defined acute kidney injury (AKI) as any kidney function at
56 admission lower than its usual value, and worsening kidney function (WKF) as kidney
57
58
59
60

1 function that decreased during hospitalisation relative to admission values.^[14] AKI and
2
3 WKF were scored according to the KDIGO classification. An absolute increase in the
4
5 creatinine value of 26.4mmol/L, or a 1.5 to <2-fold increase over the baseline creatinine
6
7 value was defined stage I. A ≥ 2 to <3-fold increase was defined as stage II and a ≥ 3 -
8
9 fold increase or use of dialysis was determined as stage III.
10
11

12
13 Comorbidity burdens were summarised using Charlson index, calculated using the
14
15 CIM-10 codes from electronic medical charts.^[16] HF types were stratified into
16
17 intermediate or reduced left ventricular ejection fraction (LVEF < 49%), preserved
18
19 LVEF (LVEF > 50%) and unknown LVEF.
20
21
22

23
24
25
26
27 We extracted urinary and blood culture information from the microbiology laboratory
28
29 database for each febrile episode during hospitalisation. A diagnosis of UTI was
30
31 defined as bacterial growth of $10E^3$ colony-forming units in a urine sample plus the
32
33 corresponding symptoms of a UTI.
34
35
36
37

38
39 Information on death was obtained from Switzerland's national deaths registry and
40
41 Geneva University Hospitals' (the only public hospital in the canton) electronic
42
43 databases. We reviewed charts for hospital LOS, place of discharge (home vs
44
45 rehabilitation centre or care home), and all-cause and HF-related hospital
46
47 readmissions within one year.
48
49
50

51 **PATIENT AND PUBLIC INVOLVEMENT**

52
53
54 Patients were not involved in the study design or conduct.
55
56

57 **STATISTICS**

1 For our analyses, timings (day 0) were set from the first day of diuretic use, which could
2 differ from the hospital admission day.
3
4

5 6 *Primary analysis and weight evolution* 7

8
9
10 Weight loss analyses during diuretic treatment were restricted to patients with volume
11 overload. The primary analysis used a linear regression model, where the 48 h weight
12 loss was the dependent variable and UC was the independent variable. The model
13 was adjusted for age (continuous), sex (binary), Charlson index score (continuous),
14 pre-admission diuretic dose (continuous), HF type (categorical), admission heart rate
15 and blood pressure (continuous), respiratory failure (binary), weight excess at diuretic
16 therapy (continuous), first diuretic dose (continuous), use of continuous intravenous
17 diuretics (binary), AKI (categorical) and admission through the emergency room
18 (binary). Adjustment factors were chosen based on clinical expertise. To reach non-
19 inferiority, the upper confidence interval of a between-group difference had to be less
20 than 1 kg (in favour of UC). The 1 kg boundary was arbitrarily chosen as a clinically
21 relevant threshold. Unilateral T-test served to test non-inferiority.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37

38 We performed three sensitivity analyses for the main outcome. Firstly, multiple
39 imputation method was used to replace missing values. Missing data, which were all
40 5% or less, were inspected to ensure that the missing at random assumption was
41 reasonable. Imputation involved all baseline responders and utilised the variables in
42 the adjusted models. Missing data were imputed using chained equations. Twenty
43 imputed datasets were generated and parameter estimates were combined using
44 Rubin's rules. The second sensitivity analysis excluded patients with urinary retention.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
The third matched catheterised patients 1:1 to non-catheterised patients according to
sex and the closest value (< 10%) of a propensity score. The score included all the

1 variables mentioned above except sex. A paired t-test was used to test mean
2
3 differences.
4
5
6
7
8
9

10 We used linear regression, adjusted for confounders, to explore associations between
11 UC and persistent weight excess at 72 h and one week. We also tested the interaction
12 between UC and time in a mixed-effects model adjusted for the factors mentioned
13 above. A random intercept for each patient accounted for repeated measures across
14 days. The mean expected excess weights of patients with and without UC was
15 calculated assuming mean values for continuous predictors and a proportion of
16 positive categorical predictors similar to the study sample.
17
18
19
20
21
22
23
24
25
26
27
28
29

30 *Clinical improvements, safety outcomes and other analyses*

31
32

33 The unadjusted impact of UC on time-dependent outcomes was analysed using
34 Kaplan–Meier survival analysis and an unweighted, two-sided, log-rank test to
35 compare groups. Analysis of target weight was restricted to patients with volume
36 overload. Analyses of intravenous diuretics, oxygen supply and CPAP were restricted
37 to patients receiving those therapies. Multivariate Cox models were adjusted for age,
38 sex and Charlson comorbidity index score. For target weight and the time needed to
39 discontinue intravenous diuretics, Cox models were further adjusted for all the
40 confounding factors in the primary analysis. The proportional hazards assumption was
41 verified using Schoenfeld residuals and a visual inspection of the log-minus-log plots.
42
43
44
45
46
47
48
49
50
51
52
53
54
55

56 The association between UC and LOS was tested using a linear regression model
57 adjusted for confounding factors and in which LOS was log-transformed to correct for
58
59
60

1 skewed data. Logistic regression was used to adjust binary outcomes for
2
3 confounders. Comparisons of characteristics between groups were performed using
4
5 the chi-squared test or Fisher's exact test, where appropriate, for categorical
6
7 variables. The Mann–Whitney test was used for continuous variables as these were
8
9 not normally distributed. Except for the primary outcomes, all analyses were two-
10
11 sided, with a significance level set at 5%. All analyses were performed using STATA,
12
13 version 12.0, and R statistical software, Version 4.0.0.[17]
14
15
16
17
18
19
20
21

22 RESULTS

23
24
25
26 Of 640 potential participants in the HF register, 174 had no available paper medical
27
28 chart and 7 had had no diuretic therapy within the first 7 days, leaving a cohort of 459
29
30 patients of whom 113 underwent UC within the first 24 h (24.6%). Only four of these
31
32 patients had documented urinary retention. Catheterised patients were older, more
33
34 often women, more frequently experienced respiratory failure or AKI, and received
35
36 higher initial diuretic doses (**Table 1**). Urinary catheters were placed for a median of 4
37
38 days (IQR: 2–8). Diuresis was recorded more often among patients with UC (58.0%)
39
40 than patients without (41.2%, $p < 0.01$).
41
42
43
44
45
46
47
48

49 EXCESS WEIGHT UNDER DIURETIC THERAPY

50
51
52 At diuretic therapy initiation, 342 patients carried excess weight and were included in
53
54 the primary analysis. In adjusted linear regressions, being catheterised was not
55
56 associated with significantly greater 48 h weight loss than not being catheterised
57
58 (0.43 Kg in favour of UC (95% CI: -0.03–0.88)). The upper confidence interval of
59
60

1 between-group difference was below the non-inferiority boundary of 1 kg ($p < 0.01$ for
2 non-inferiority).
3
4

5
6 In sensitivity analysis, the results were in line with the primary analysis. The difference
7 in 48 h weight loss, after multiple imputation for missing values, was 0.33 kg (95% CI:
8 -0.1–0.76; $p < 0.01$ for non-inferiority). Excluding patients with urinary retention ($n = 4$)
9 did not change the results (data not shown). In the last sensitivity analysis, 64 patients
10 with UC were matched with 64 patients without one (none had urinary retention). The
11 difference in weight loss was 0.29 kg (95% CI: -0.3–0.88; $p < 0.01$ for non-inferiority).
12
13
14
15
16
17
18
19
20
21
22
23
24

25 Patients with UC did not have a statistically lower persistent excess weight at 72 h: the
26 difference was 0.27 kg (95% CI: -0.52–1.1; $p = 0.50$) in unadjusted and 0.24 kg
27 (95% CI: -0.17–0.64; $p < 0.001$ for non-inferiority) in adjusted linear regression. At one
28 week, the excess weight difference between patients with and without UC was -0.09 kg
29 (95% CI: -1.0–0.8; $p = 0.84$) in unadjusted and -0.14 kg (95% CI: -0.89–0.60; $p = 0.01$
30 for non-inferiority) in adjusted linear regression. Similarly, there was no statistically
31 significant interaction between UC and daily excess weight changes in the mixed-
32 effects model ($p = 0.55$; **Figure 1**).
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

48 **CLINICAL IMPROVEMENT**

49
50 Time to reach target weight and time needed to discontinue CPAP were not statistically
51 different between patients with and without UC in both unadjusted and adjusted
52 analysis (**Figure 2, Table 2**). UC tended to be associated with a longer time to
53 discontinuation of an intravenous diuretic or discontinuation of oxygen supply (**Figure**
54 **2**), but the associations disappeared after adjustment for confounders (**Table 2**).
55
56
57
58
59
60

1
2
3
4 The median hospital LOS was identical for patients with and without UC (12 days, IQR:
5 9–18). However, fewer UC patients were discharged directly home from hospital
6
7 (57.3% vs 73.7%; adjusted OR 0.6 (95% CI: 0.3–0.9; $p < 0.01$)).
8
9
10
11
12
13
14

15 SAFETY OUTCOMES

16
17
18 The proportions of initial treatment failures, low blood pressure episodes and patients
19 with worsening kidney function were not statistically different between groups (**Table**
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

All-cause and HF-related readmissions were not statistically different between patients with and without UC (**Table 2** and **Figure 3**). Half the patients with UC and one third without UC were dead at one year. The difference was not statistically significant after adjustment (**Table 2**).

UC patients were at a higher risk of suffering from a UTI, and this association persisted in adjusted analyses (**Table 2** and **Figure 3**). Multiple UTIs occurred in 9 UC patients (8.0%) and in 5 patients without UC (1.2%, $p < 0.01$). Patients with a UTI had a longer hospital LOS (15 days (IQR: 10–21) vs 11 days (IQR: 8–17), $p < 0.001$) and an increased one-year mortality rate (52.5% vs 34.0%, adjusted HR 1.5; 95% CI: 1.1–2.3; $p = 0.038$).

DISCUSSION AND CONCLUSION

Among patients admitted to medical wards for acute HF, initial weight loss was not different for the strategy of abstaining from UC compared to UC placement within the first 24 h. Besides, UC had no impact on clinical improvement such as the time needed to reach target weight, discontinue intravenous diuretics or improve respiratory failure, and hospital LOS. Furthermore, UC did not prevent excessive diuresis resulting in low blood pressure episodes or worsening kidney function. However, UC was associated with a higher risk of a UTI.

There are few appropriate indications for UC,^[11] and 7% to 50% of UCs are done outside these indications.^[18, 19] Rates of UC subsequent to HF vary greatly and could be very high. In one study, more than half of haemodynamically stable patients underwent UC.^[8] The rationale for UC in HF is weak yet somehow based on beliefs that it facilitates urine elimination and increases comfort by decreasing toilet visits. However, there is good evidence that UC does not increase the comfort of patients undergoing diuretic therapy, even at high dosages.^[10] Most guidelines on UC good practice do not list HF as a standard indication.^[20] Through their *Choosing Wisely* campaigns, Swiss and American authorities recommend avoiding in-dwelling UC for urine output monitoring in stable patients who can void or for patient or staff convenience.^[21, 22] Indication lists, authorities' recommendations and financial penalties have reduced the overall inappropriate use of UC.^[11] An American study showed that the proportion of UC among HF patients decreased by 8% between 2009 and 2014.^[7]

1 Catheter-associated UTIs (CAUTIs) are the second most common infections
2 associated with patients hospitalised for HF after *Clostridium*-related infections.[²³]
3
4 Previous reports among HF patients found associations between CAUTI and increased
5
6 risks of discharge to a skilled care facility, longer hospital LOS, higher total hospital
7
8 costs and in-hospital mortality.[^{8, 23}] Condom catheters are a better option when
9
10 diuresis affects older patients with a disability: they lead to fewer complications,[²⁴] are
11
12 more comfortable and are less painful than UC.[¹⁰]
13
14
15
16
17
18
19
20
21

22 The present study is the first to give an insight into the hypothetical clinically relevant
23
24 benefits of UC in the context of HF. Using a register of prospective records and
25
26 significant adjustments to potential confounding factors (some collected
27
28 retrospectively) further strengthened our findings. However, the study has limitations.
29
30 Firstly, the cohort preceded some important advances in HF management (e.g.:
31
32 sacubitril treatment or SGLT2 inhibitors) that may have changed readmission risk and
33
34 mortality. Nevertheless, there were no changes in the 2021 ESC guidelines concerning
35
36 the management of acute HF using diuretics, or the relevance of UC insertion in this
37
38 indication.[²⁵] We thus believe that our study's conclusions remain valid today.
39
40
41 Secondly, the study's retrospective, observational approach only allowed us to
42
43 hypothesise that urinary catheters were placed for HF management or to facilitate
44
45 diuresis. To minimise these issues, we only selected UCs which occurred in the first
46
47 24 h of diuretic therapy. Thirdly, since patients are usually not weighed in emergency
48
49 rooms, we focused on the weight change from days 1 to day 3. Thus, UC's impact
50
51 during the first 24 h of diuretic therapy was not assessed. A randomised prospective
52
53 design, with protocols to guide rapid diuretic adaptation, would be better able to explore
54
55 the UC's real potential among HF patients. However, considering current evidence and
56
57
58
59
60

1 risks, such a study may never occur. It is of note that records of the amount of urine
2
3
4 passed were only available for half of the patients, with or without UC. Thus, checking
5
6 for adequate diuresis after treatment with diuretics might be a simpler, safer
7
8 recommendation than UC for improved HF management. Finally, some medical charts
9
10 could not be retrieved, but their unavailability was random and unrelated to their UC
11
12 status or outcomes. Thus, there is little risk that unavailable charts biased the results.
13
14
15
16
17
18

19 In this retrospective study, with no obvious hourly diuresis-based diuretic adjustment
20
21 strategy, UC within 24 h of diuretic therapy initiation had no proven impact on the
22
23 clinically relevant outcomes of time to reach target weight, time to resolve respiratory
24
25 failure and hospital LOS. The lack of benefits and the increased risk of a UTI preclude
26
27 systematic UC for the management of HF.
28
29
30
31

32 **DATA AVAILABILITY**

33
34
35
36 The database, variable explanation, and Stata do-file (in Word format) are available at
37
38 request to gregor.john@h-ne.ch.
39
40
41
42
43
44

45 **REFERENCES**

- 46
47
48
49 1. Savarese, G., Lund, L. H. Global Public Health Burden of Heart Failure. *Card Fail Rev.* **3**, 7-11
50
51 (2017).
52
53
54 2. Benjamin, E. J. *et al.* Heart Disease and Stroke Statistics-2019 Update: A Report From the
55
56 American Heart Association. *Circulation.* **139**, e56-e528 (2019).
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
3. Jessup, M. *et al.* 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. *Circulation*. **119**, 1977-2016 (2009).
4. McMurray, J. J. *et al.* ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. *Eur Heart J*. **33**, 1787-847 (2012).
5. Felker, G. M. *et al.* Diuretic strategies in patients with acute decompensated heart failure. *N Engl J Med*. **364**, 797-805 (2011).
6. Felker, G. M., O'Connor, C. M., Braunwald, E. Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil? *Circ Heart Fail*. **2**, 56-62 (2009).
7. Metersky, M. L. *et al.* National trends in the frequency of bladder catheterization and physician-diagnosed catheter-associated urinary tract infections: Results from the Medicare Patient Safety Monitoring System. *Am J Infect Control*. **45**, 901-04 (2017).
8. Jang, A. Y. *et al.* Routine Indwelling Urethral Catheterization in Acute Heart Failure Patients Is Associated With Increased Urinary Tract Complications Without Improved Heart Failure Outcomes. *Circ J*. **82**, 1632-39 (2018).
9. Aoki, T. Appropriate Use of Urinary Catheter in Acute Heart Failure Patients. *Circ J*. **82**, 1505-06 (2018).
10. Saint, S. *et al.* Condom versus indwelling urinary catheters: a randomized trial. *J Am Geriatr Soc*. **54**, 1055-61 (2006).

- 1 11. Meddings, J. *et al.* Reducing unnecessary urinary catheter use and other strategies to
2 prevent catheter-associated urinary tract infection: an integrative review. *BMJ Qual*
3
4 *Saf.* **23**, 277-89 (2014).
5
6
7
- 8 12. Hollingsworth, J. M. *et al.* Determining the noninfectious complications of indwelling
9 urethral catheters: a systematic review and meta-analysis. *Ann Intern Med.* **159**, 401-
10
11
12
13 10 (2013).
14
15
- 16 13. Garin, N. *et al.* Inclusion into a heart failure critical pathway reduces the risk of death or
17 readmission after hospital discharge. *Eur J Intern Med.* **23**, 760-4 (2012).
18
19
- 20 14. Berra, G. *et al.* Outcome in acute heart failure: prognostic value of acute kidney injury and
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
15. Anisman SD, Erickson SB, Morden NE. How to prescribe loop diuretics in oedema. *BMJ.*
364; l359 (2019).
16. Sundararajan, V. *et al.* New ICD-10 version of the Charlson comorbidity index predicted in-
hospital mortality. *J Clin Epidemiol.* **57**, 1288-94 (2004).
17. R Core Team (2017). R: A language and environment for statistical computing. [program],
2019. R Foundation for Statistical Computing, Vienna, Austria. URL [https://www.R-
project.org/](https://www.R-project.org/).
18. Saint, S. *et al.* Are physicians aware of which of their patients have indwelling urinary
catheters? *Am J Med.* **109**, 476-80 (2000).
19. Gokula, R. R., Hickner, J. A., Smith, M. A. Inappropriate use of urinary catheters in elderly
patients at a midwestern community teaching hospital. *Am J Infect Control.* **32**, 196-9
(2004).
20. Centers for Disease Control and Prevention. Examples of Appropriate Indications for
Indwelling Urethral Catheter Use. URL:

1 <https://www.cdc.gov/infectioncontrol/guidelines/cauti/recommendations.html> (last
2
3
4 access: 09.04.2020)
5

6 21. Physicians ACoE. Choosing Wisely, 2013. URL:

7
8 [https://www.choosingwisely.org/societies/american-college-of-emergency-
9
10
11 physicians/](https://www.choosingwisely.org/societies/american-college-of-emergency-physicians/) (last access: 09.04.2020)
12

13 22. Générale SSdmi. Choosing Wisely, 2016. URL: [https://www.smartermedicine.ch/fr/liste-
14
15 top-5/infektiologie.html#c15766](https://www.smartermedicine.ch/fr/liste-top-5/infektiologie.html#c15766) (last access: 09.04.2020)
16
17

18 23. Miller, P. E. *et al.* National Trends in Healthcare-Associated Infections for Five Common
19
20 Cardiovascular Conditions. *Am J Cardiol.* **124**, 1140-48 (2019).
21
22

23 24. Saint, S. *et al.* Condom Catheters versus Indwelling Urethral Catheters in Men: A
24
25 Prospective, Observational Study. *J Hosp Med.* **14**, E1-E4 (2019).
26
27

28 25. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC
29
30 Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart*
31
32
33 *J.* **36**, 3599-726 (2021).
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ACKNOWLEDGEMENTS

Contributor: We gratefully acknowledge Elise Dupuis for her help with the statistical analysis.

Funders: The study received a grant from Geneva University Hospitals (grant: PRD 1-2017-I).

AUTHORS CONTRIBUTIONS

G.J., S.C., N.G., D.C. and J.S.: planned the study (protocol). **M.A. and G.B.** collected the data. **G.J. and J.S.** performed the analyses. **G.J.** wrote the manuscript. All authors reviewed and approved the final manuscript.

CONFLICT OF INTEREST STATEMENT

The authors declare no competing interests.

ABBREVIATIONS

AKI: acute kidney injury

CI: confidence interval

CPAP: continuous positive airway pressure HF: heart failure

HR: hazard ratio

HUG: Geneva University Hospitals

1 KDIGO: Kidney Disease: Improving Global Outcomes
2

3 LVEF: left ventricular ejection fraction
4

5 OR: odds ratio UC: urinary catheterisation
6

7
8 UTI: urinary tract infection
9

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4 **Figure 1:** Predicted excess weight for patients with (black line) and without (green line) urinary
5 catheterisation (UC). Mean expected excess weights and their confidence intervals were
6 calculated using an adjusted mixed-effects model assuming mean values for continuous
7 predictors and a proportion of positive categorical predictors similar to the study sample. UC
8 had no statistical effect on excess weight evolution over time (p for interaction = 0.55).
9
10
11
12
13
14
15
16
17
18
19
20
21

22 **Figure 2:** Time to reach clinical improvement for patients with urinary catheterisation (black
23 line) and controls (green line): (A) time to reach target weight; (B) time to discontinuation of
24 intravenous diuretics; (C) time to discontinuation of continuous positive airway pressure
25 therapy; and (D) time to discontinuation of oxygen supply.
26
27
28
29
30
31
32
33
34
35
36
37
38

39 **Figure 3:** Time to reach unfavourable outcomes for patients with urinary catheterisation (black
40 line) and controls (green line): (A) time to first urinary tract infection; (B) time to first all-cause
41 hospital readmission; (C) time to first heart failure-related readmission; and (D) time to death.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1: Characteristics of participants with and without urinary catheterisation (UC). Only UC within 24 h of diuretic therapy initiation was considered. Values are numbers (percentage) unless otherwise stated.


Characteristic	Cohort (N = 459)	With UC (N = 113)	Without UC N = 346)	P value
Age (y), median (IQR)	81 (73–86)	83.5 (76–89)	80 (71–85)	< 0.001
Male	248 (55.2%)	52 (47.3%)	196 (57.8%)	0.053
Admitted through ER	398 (86.7%)	97 (85.8%)	301 (87.0%)	0.754
Night-time admission (19h00–07h00)	169 (36.8%)	37 (32.7%)	132 (38.1%)	0.301
Current smoker	79 (18.0%)	18 (17.3%)	61 (18.1%)	0.844*
High blood pressure	331 (73.7%)	83 (73.7%)	248 (73.2%)	0.709
Diabetes	135 (30.1%)	34 (30.9%)	101 (29.8%)	0.812
Myocardial infarct	27 (6.1%)	6 (5.5%)	21 (6.3%)	0.762*
FEVG<50%	203 (45.2%)	46 (40.7%)	157 (45.4%)	0.686
Stroke	52 (11.8%)	18 (16.1%)	34 (10.2%)	0.076*
Peripheral vascular disease	76 (17.2%)	23 (21.1%)	53 (15.9%)	0.242*
Dementia	30 (6.8%)	9 (8.3%)	21 (6.3%)	0.482*
COPD	66 (14.7%)	16 (14.5%)	50 (14.7%)	0.958*
Oncological disease	32 (7.2%)	8 (7.3%)	24 (7.2%)	0.963*
Liver disease	24 (5.4%)	7 (6.4%)	17 (5.1%)	0.598*
CKD				
II	174 (38.7%)	39 (35.4%)	135 (39.2%)	0.380
III	154 (34.4%)	40 (36.4%)	114 (33.6%)	
IV	22 (4.9%)	6 (5.5%)	16 (4.7%)	
V	2 (0.5%)	0	2 (0.6%)	
Charlson comorbidity index, median (IQR)	3 (1–4)	3 (2–4)	3 (1–4)	0.115
Pre-admission medication				
ACE/ARB	290 (64.6%)	65 (59.1%)	225 (66.4%)	0.165
Beta-blocker	204 (45.4%)	49 (44.5%)	155 (45.7%)	0.829
Aldosterone inhibitor	62 (13.8%)	14 (12.7%)	48 (14.2%)	0.753*
Diuretics	239 (52.1%)	66 (58.4%)	173 (50.0%)	0.120
Admission characteristics				
Median sodium level (mmol/l) at admission (IQR)	137 (134–140)	137 (133–139)	138 (135–140)	0.022
Median NT-proBNP level (ng/l) at admission (IQR)	6377 (3069–13254)	7700 (4080–16204)	6206 (2700–12101)	0.124
Median haemoglobin level (g/l) at admission (IQR)	123 (109–137)	119 (107–133)	125 (110–138)	0.115
Median creatinin level (mmol/l) at admission (IQR)	107 (85–148)	116 (89–197)	104 (83–138)	0.005
Heart rate (beat/min), median (IQR)	81 (70–94)	82.5 (70–91)	80 (69.5–95)	0.785
Mean blood pressure (mmHg), median (IQR)	90 (80–100)	88.3 (78.3–100)	90 (80.3–100)	0.162
AKI				
I	143 (31.5%)	46 (41.8%)	97 (28.6%)	0.002*
II	24 (5.3%)	9 (8.2%)	15 (4.4%)	
III	5 (1.1%)	3 (2.7%)	2 (0.6%)	
Respiratory failure:	371 (80.8%)	105 (92.9%)	266 (76.9%)	< 0.001*
- Needs oxygen supply	365 (79.5%)	104 (92.0%)	261 (75.4%)	
- CPAP	75 (16.3%)	27 (23.9%)	48 (13.9%)	
Volume overload	342 (74.5%)	86 (76.1%)	256 (74.0%)	0.654
- Target weight (kg), median (IQR)	69.2 (58.1–80.8)	70 (58–81.4)	68.7 (58.6–80.5)	
Intravenous therapy	431 (93.9%)	108 (95.6%)	323 (93.4%)	0.391*
Continuous intravenous diuretic therapy	42 (9.2%)	15 (13.4%)	27 (7.8%)	0.076*

1	Initial diuretic doses (mg), median	40 (30–80)	60 (40–90)	40 (20–60)	< 0.001
2	(IQR)				
3	* Fischer test				
4	ACE, angiotensin-converting-enzyme inhibitor; AKI, acute kidney injury; ARB, angiotensin receptor				
5	blockers; CKD, chronic kidney disease by CKD-EPI classification; COPD, chronic obstructive				
6	pulmonary disease; CPAP, continuous positive airway pressure therapy; ER, emergency room; UC:				
7	urinary catheterisation				
8					
9					
10					
11					
12					
13					
14					
15					
16					
17					
18					
19					
20					
21					
22					
23					
24					
25					
26					
27					
28					
29					
30					
31					
32					
33					
34					
35					
36					
37					
38					
39					
40					
41					
42					
43					
44					
45					
46					
47					
48					
49					
50					
51					
52					
53					
54					
55					
56					
57					
58					
59					
60					

For peer review only


Table 2: Clinical improvements and adverse outcomes with and without urinary catheterisation. Values are numbers unless otherwise stated.

Time to clinical improvement	With UC	Without UC	HR	Adjusted HR
Time to target weight (d), median (IQR)	6 (3–7)	6 (3–7)	1.1 (0.8–1.5)	1.0 (0.7–1.5)
Time to switch/discontinuation of intravenous diuretics (d), median (IQR)	4 (2–8)	3 (1–6)	0.8 (0.7–1.0)	0.9 (0.7–1.2)
Time to discontinuation of CPAP (d), median (IQR)	4 (2–6)	4 (2–5)	1.2 (0.7–2.2)	1.1 (0.5–2.4)
Time to discontinuation of oxygen supply (d), median (IQR)	4 (2–8)	3 (1–7)	0.8 (0.6–1.0)	0.9 (0.7–1.2)
Time to adverse events	With UC	Without UC	HR	Adjusted HR
Urinary tract infection, n (%)	37 (32.7%)	46 (13.3%)	2.9 (1.8–4.8)*	2.5 (1.5–4.2)*
One-year all-cause hospital readmission, n (%)	56 (50.9%)	193 (56.9%)	1.1 (0.8–1.4)	1.1 (0.8–1.4)
One-year heart failure-related hospital readmission, n (%)	28 (25.5%)	91 (26.8%)	1.1 (0.7–1.7)	1.1 (0.7–1.7)
One-year mortality, n (%)	51 (50.0%)	101 (33.4%)	1.7 (1.2–2.4)*	1.4 (1.0–2.1)
Other secondary outcomes	With UC	Without UC	OR	Adjusted OR
Initial treatment failure	23 (26.7%)	78 (30.5%)	0.8 (0.5–1.4)	0.8 (0.4–1.4)
Low blood pressure episode	49 (43.7%)	154 (44.6%)	1.0 (0.6–1.5)	1.1 (0.7–1.7)
- Need of saline perfusion	24/49 (49.0)	67/154 (43.5)		
Worsening of renal function				
0	82 (74.6%)	260 (76.7%)	1.1 (0.7–1.8)†	1.1 (0.7–1.8)†
1	27 (24.6%)	73 (21.5%)		
2	1 (-)	6 (1.8%)		
* <i>p</i> value < 0.05; † OR of changing to a worse category				
CPAP, continuous positive airway pressure therapy; UC, urinary catheterisation				




Predicted excess weight for patients with (black line) and without (green line) urinary catheterisation (UC). Mean expected excess weights and their confidence intervals were calculated using an adjusted mixed-effects model assuming mean values for continuous predictors and a proportion of positive categorical predictors similar to the study sample. UC had no statistical effect on excess weight evolution over time (p for interaction = 0.55).

296x209mm (150 x 150 DPI)



Time to reach clinical improvement for patients with urinary catheterisation (black line) and controls (green line): (A) time to reach target weight; (B) time to discontinuation of intravenous diuretics; (C) time to discontinuation of continuous positive airway pressure supply; and (D) time to discontinuation of oxygen supply.

244x178mm (72 x 72 DPI)



Time to reach unfavourable outcomes for patients with urinary catheterisation (black line) and controls (green line): (A) time to first urinary tract infection; (B) time to first all-cause hospital readmission; (C) time to first heart failure-related readmission; and (D) time to death.

244x178mm (72 x 72 DPI)

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No.	Recommendation	Page No.	Relevant text from manuscript
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1, 3	
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3,4	
Introduction				
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5	
Objectives	3	State specific objectives, including any prespecified hypotheses	5-6	
Methods				
Study design	4	Present key elements of study design early in the paper	6	
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6-7	
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	6-7	
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	10-11	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	9	
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	9	
Bias	9	Describe any efforts to address potential sources of bias	10	
Study size	10	Explain how the study size was arrived at	NA	

Continued on next page

Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	10
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	9-11
		(b) Describe any methods used to examine subgroups and interactions	NA
		(c) Explain how missing data were addressed	6
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed	10-11
		<i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	10
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	12-14, table 1-2
		(b) Give reasons for non-participation at each stage	
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Table 1
		(b) Indicate number of participants with missing data for each variable of interest	12
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	Figure2-3
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	Figure2-3
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	NA
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Table2
		(b) Report category boundaries when continuous variables were categorized	
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	

Continued on next page

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	12
Discussion			
Key results	18	Summarise key results with reference to study objectives	14
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	16
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	16
Generalisability	21	Discuss the generalisability (external validity) of the study results	16
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	16-17

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Risks and benefits of urinary catheterisation during inpatient diuretic therapy for acute heart failure: A retrospective, non-inferiority, cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-053632.R2
Article Type:	Original research
Date Submitted by the Author:	14-Jun-2022
Complete List of Authors:	John, Gregor; Hôpitaux Universitaires Genève, Department of Internal Medicine; Université de Genève, Department of Medicine Arcens, Marc; Hôpitaux Universitaires Genève, Department of Medicine Berra, Gregory; Hôpitaux Universitaires Genève, Department of Medicine Garin, Nicolas; Hôpitaux Universitaires Genève, Department of Medicine; Université de Genève Carballo, David ; Université de Genève; Hôpitaux Universitaires Genève, Department of Medicine Carballo, Sebastian; Hôpitaux Universitaires Genève, Department of Medicine; Université de Genève Stirнемann, Jerome; Hôpitaux Universitaires Genève, Department of Medicine; Université de Genève
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Medical management, Infectious diseases, Geriatric medicine, Evidence based practice
Keywords:	Heart failure < CARDIOLOGY, Urinary tract infections < UROLOGY, Health & safety < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Title: Risks and benefits of urinary catheterisation during inpatient diuretic therapy for acute heart failure: A retrospective, non-inferiority, cohort study

Running headline: urinary catheterisation in acute heart failure.

Gregor John^{1,2,3*}, Marc Arcens², Gregory Berra², Nicolas Garin^{2,3}, David Carballo^{3,4}, Sebastian Carballo^{2,3}, Jérôme Stirnemann^{2,3}.

1. Department of Internal Medicine, Neuchâtel Hospital Network, Rue de la Maladière 45, CH-2000 Neuchâtel, Switzerland

2. Department of Medicine, Geneva University Hospitals (HUG), Gabrielle-Perret-Gentil 4, CH-1205 Geneva, Switzerland; Fax: 0041 32 967 27 29, Phone: 0041 79 559 59 29; gregor.john@h-ne.ch (may be published).

3. Geneva university, Michel-Servet 1, 1211 Genève 4, Switzerland.

4. Cardiology Service, Department of Medicine, Geneva University Hospitals (HUG), Gabrielle-Perret-Gentil 4, CH-1205 Geneva, david.carballo@hcuge.ch

***Gregor John^{1,2,3*}**, PD, MD (correspondence and requests for reprints); Department of Internal Medicine, Neuchâtel Hospital Network, Rue de la Maladière 45, CH-2000 Neuchâtel, Switzerland. Fax: 0041 32 967 27 29, Phone: 0041 79 559 59 29; gregor.john@h-ne.ch (may be published).

Number of References: 30, **Tables:** 2, **Figures:** 3, and **Appendix:** 7

Word counts: Abstract: 295; Text: 2977

Keywords: Heart-failure, diuretics, urinary catheter, non-inferiority study, hospital readmission, mortality

ABSTRACT:

Objectives: Patients with acute congestive heart failure (HF) regularly undergo urinary catheterisation (UC) at hospital admission. We hypothesised that UC has no clinical benefits with regard to weight loss during inpatient diuretic therapy for acute congestive HF and increases the risk of urinary tract infection (UTI).

Design: Retrospective, non-inferiority study.

Setting: Geneva University Hospitals' Department of Medicine, a tertiary centre.

Participants: In a cohort of HF patients, those catheterised within 24 h of diuretic therapy (n=113) were compared with non-catheterised patients (n=346).

Primary and secondary outcome measures: The primary endpoint was weight loss 48 h after starting diuretic therapy. Secondary endpoints were time needed to reach target weight, discontinuation of intravenous diuretics, and resolution of respiratory failure. Complications included the time to a first UTI, first hospital readmission and death.

Results: 48 h weight loss was not statistically different between groups and the adjusted difference was below the non-inferiority boundary of 1 kg (0.43 kg (95% CI: -0.03–0.88) in favour of UC, $p < 0.01$ for non-inferiority). UC was not associated with time to reaching target weight (adjusted HR 1.0; 95%CI: 0.7–1.5), discontinuation of intravenous diuretics (aHR 0.9; 95%CI: 0.7–1.2), or resolution of respiratory failure (aHR 1.1; 95%CI: 0.5–2.4). UC increased the risk of UTI (aHR 2.5; 95%CI: 1.5–4.2) but was not associated with hospital readmission (aHR 1.1, 95%CI: 0.8–1.4) or one-year mortality (aHR 1.4; 95%CI: 1.0–2.1).

Conclusion: In this retrospective study, with no obvious hourly diuresis-based diuretic adjustment strategy, weight loss without UC was not inferior to weight loss after UC

1 within 24 h of initiating diuretic treatment. UC had no impact on clinical improvement
2
3 and increased the risk of UTI. This evidence, therefore, argues against the systematic
4
5 use of UC during a diuretic therapy for HF.
6
7
8
9
10

11 **‘STRENGTHS AND LIMITATIONS OF THIS STUDY’**

- 17 • The present study is the first to give an insight into the hypothetical clinically
18 relevant benefits of UC in the context of HF.
19
- 20 • The preceded the advent of sacubitril or SGLT2 inhibitors therapy.
21
22 Nevertheless, in 2021, updated ESC guidelines did not evolve regarding
23
24 diuretics or the relevance of UC insertion for the management of acute
25
26 decompensate HF.
27
- 28 • The study’s retrospective, observational approach only allowed us to
29
30 hypothesise that urinary catheters were placed for HF management or to
31
32 facilitate diuresis.
33
- 34 • Since patients are usually not weighed in emergency rooms, we focused on the
35
36 weight change from days 1 to day 3. Thus, UC’s impact during the first 24 h of
37
38 diuretic therapy was not assessed.
39
- 40 • A randomised prospective design, with protocols to guide rapid diuretic
41
42 adaptation, would be better able to explore the UC’s real potential among HF
43
44 patients. However, considering current evidence and risks, such a study may
45
46 never occur.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION:

Heart failure (HF) is a major public health concern, affecting 2% of the developed world's population.^[1] Patients with HF are hospitalised about once a year, on average.^[2] Due to population aging and the growing prevalence of comorbidities, the absolute number of hospital admissions for HF is expected to increase by as much as 50% over the next 25 years.^[1, 3, 4]

Diuretics are the mainstay treatments for volume overload.^[5, 6] Nevertheless, overly aggressive or insufficient treatments can result in acute kidney injury, electrolytic imbalance, low blood pressure, prolonged hospital length of stay (LOS) or early hospital readmission.^[7, 8] Assessing adequate response to diuretics, e.g. measuring diuresis, is therefore important and enables rapid treatment adjustment. This may be as or even more useful than how diuretics are initially administered.^[7, 9]

Between one quarter ^[10] and one half of patients ^[11] hospitalised for HF undergoes in-dwelling urinary catheter placement (UC). The rationale for UC in this population sometimes includes managing hypervolemia ^[11, 12] or improving comfort during diuretic treatment.^[13] By maximising the elimination of liquids while avoiding excessive losses, UC could theoretically have a positive impact on hospital LOS, readmission rates and even death. Although the benefits of UC remain uncertain, the risks of increased urinary tract infections (UTI) and traumatic complications are well known.^[11, 14, 15] A recent retrospective study of catheterised HF patients showed no impact on LOS and an increased risk of infection.^[11] Little evidence exists on UC's impact on clinically relevant improvements such as weight loss, time to improvement

1 of respiratory failure or time to discontinuation of intravenous therapy. The present
2
3 study aimed to determine the risks and clinical benefits of UC among patients
4
5 hospitalised for congestive HF, with the a priori hypothesis that HF management with
6
7 UC is not better than without it.
8
9

10 11 12 13 14 15 **PATIENTS AND METHODS** 16

17
18
19 We conducted a retrospective, non-inferiority, cohort study using a pre-existing cohort
20
21 of patients admitted to Geneva University Hospitals' Department of Medicine for acute
22
23 HF between 01.01.2006 and 01.01.2010.^[16, 17] Patients were followed for one year or
24
25 until death. The institutional review board approved the study and the need for informed
26
27 consent to collect retrospectively information, was waived by the ethics committee
28
29 (Comission cantonale d'éthique de la recherche (CCER)). Reporting and analyses
30
31 were performed according to the Strengthening the Reporting of Observational Studies
32
33 in Epidemiology (STROBE) statement.
34
35
36
37
38
39
40

41 **STUDY POPULATION** 42

43
44
45 All patients aged 18 years old or more, requiring hospital admission for a primary
46
47 symptom of dyspnoea and a diagnosis of acute decompensated HF were eligible.^{[16,}
48
49 ^{17]} Acute decompensated HF was diagnosed from patients' clinical presentation, risk
50
51 factors and treatment responsiveness and/or was supported by structural or functional
52
53 echocardiographic anomalies. Patients with a final diagnosis other than HF that
54
55 explained their dyspnoea, with a low NT-proBNP level (<300ng/l), who were admitted
56
57 to the intensive care unit, whose paper medical charts for the index admission were
58
59
60

1 unavailable or who did not receive diuretics during their first seven days of
2
3 hospitalisation were excluded. We compared patients who underwent UC insertion
4
5 within 24 h of diuretic therapy initiation with those not catheterised.
6
7
8
9
10

11 **OUTCOMES**

12
13
14
15 The primary endpoint was the 48 h weight loss after starting diuretic therapy.
16
17 Secondary endpoints were persistent excess weight at 72 h and at one week, the time
18
19 needed to reach clinical improvement (reaching target weight (+/- 0.5 kg),
20
21 discontinuation of intravenous diuretics, oxygen supply and continuous positive airway
22
23 pressure (CPAP)), and hospital LOS.
24
25
26
27
28
29

30 Complications included the proportion of patients with UTI, initial diuretic treatment
31
32 failure, worsening kidney function and episodes of low blood pressure, and time to a
33
34 first UTI, first hospital readmission and death. Initial treatment failure was defined as a
35
36 need for increased doses of diuretics, or a switch from oral to intravenous diuretic
37
38 therapy or from a bolus to a continuous intravenous diuretic therapy two days or more
39
40 after the initiation of diuretics. Diuretic dose increases before that point were
41
42 considered to be usual treatment adjustments.
43
44
45
46
47
48
49

50 **DATA COLLECTION AND VARIABLE DEFINITION**

51
52
53 Data extracted from medical charts included pre-admission diuretic use, micturition
54
55 volumes during diuretic therapy, weight at discharge and, for the first seven days, daily
56
57
58
59
60

1 information on the UC, weight, diuretics administration, clinical parameters, oxygen
2 supply and use of CPAP therapy.
3
4
5
6
7
8
9

10 Volume overload (hypervolaemia) was defined as excess weight at diuretic therapy.
11 We calculated excess weight by subtracting target weight from other weights
12 measured during hospitalisation. Target weight was defined as the patient's weight at
13 discharge or, when unavailable, the lowest weight during hospitalisation that did not
14 result in increased creatinaemia or low blood pressure. Since patients are not always
15 weighed on admission day, 48 h weight loss was calculated between days 1 and 3
16 after starting diuretic therapy (day 0). When weight on day 1 or on day 3 was missing,
17 we took double the mean daily weight loss calculated between day 0 and day 4.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32

33 Respiratory failure was defined as the need for oxygen supply or CPAP. We noted
34 episodes of low blood pressure (systolic pressure < 100 mmHg) and the need for
35 saline perfusion. Daily doses of torasemide were multiplied by two and doses of oral
36 furosemide were divided by two to convert daily diuretics use into an equivalent
37 intravenous furosemide dosage.^[18]
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

We obtained patients' habitual kidney function from their general practitioner.^[17]
Kidney function at hospital admission and during the first week was extracted from the
laboratory database. We defined acute kidney injury (AKI) as any kidney function at
admission lower than its usual value, and worsening kidney function (WKF) as kidney
function that decreased during hospitalisation relative to admission values.^[17] AKI and
WKF were scored according to the KDIGO classification. An absolute increase in the

1 creatinine value of 26.4 mmol/L, or a 1.5 to <2-fold increase over the baseline
2
3 creatinine value was defined stage I. A ≥ 2 to <3-fold increase was defined as stage II
4
5 and a ≥ 3 -fold increase or use of dialysis was determined as stage III.
6
7

8
9 Comorbidity burdens were summarised using Charlson index, calculated using the
10
11 CIM-10 codes from electronic medical charts.^[19] HF types were stratified into
12
13 intermediate or reduced left ventricular ejection fraction (LVEF < 49%), preserved
14
15 LVEF (LVEF > 50%) and unknown LVEF.
16
17

18
19
20
21
22 We extracted urinary and blood culture information from the microbiology laboratory
23
24 database for each febrile episode during hospitalisation. A diagnosis of UTI was
25
26 defined as bacterial growth of $10E^3$ colony-forming units in a urine sample plus the
27
28 corresponding symptoms of a UTI.
29
30

31
32
33
34 Information on death was obtained from Switzerland's national deaths registry and
35
36 Geneva University Hospitals' (the only public hospital in the canton) electronic
37
38 databases. We reviewed charts for hospital LOS, place of discharge (home vs
39
40 rehabilitation centre or care home), and all-cause and HF-related hospital
41
42 readmissions within one year.
43
44
45
46
47
48
49

50 **PATIENT AND PUBLIC INVOLVEMENT**

51
52 Patients were not involved in the study design or conduct.
53
54
55
56
57
58

59 **STATISTICS**

1 For our analyses, timings (day 0) were set from the first day of diuretic use, which could
2 differ from the hospital admission day.
3
4

5 6 *Primary analysis and weight evolution* 7

8
9
10 Weight loss analyses during diuretic treatment were restricted to patients with volume
11 overload (Figure S1). The primary analysis used a linear regression model, where the
12 48 h weight loss was the dependent variable and UC was the independent variable.
13
14 The model was adjusted for age, sex, Charlson index score, pre-admission diuretic
15 dose, HF type, admission heart rate and blood pressure, respiratory failure, weight
16 excess at diuretic therapy, first diuretic dose, use of continuous intravenous diuretics,
17 AKI and admission through the emergency room, based on previous studies (Table
18 S1). [9, 20, 21] To reach non-inferiority, the upper confidence interval of a between-group
19 difference had to be less than 1 kg (in favour of UC). This threshold was determined
20 based on daily minimal clinically significant weight loss of 0.5 kg (1 kg in 2 days;
21 Statistics S1). [22] Unilateral T-test served to test non-inferiority.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39

40 We performed five sensitivity analyses on the main outcome (Statistics S2). Firstly, a
41 multiple imputation method was used to replace missing values. The second matched
42 catheterised patients 1:1 with non-catheterised patients according to sex and the
43 closest value (< 10%) of a propensity score. The score included all the variables
44 mentioned above except sex. A paired t-test was used to test mean differences. The
45 third sensitivity analysis excluded patients with urinary retention. The fourth replaced
46 AKI at admission with creatininemia and blood sodium. The last sensitivity analysis
47 split the continuous confounding variables at their median.
48
49
50
51
52
53
54
55
56
57
58
59
60

1 We used linear regression, adjusted for confounders, to explore associations between
2 UC and persistent weight excess at 72 h and one week. We also tested the interaction
3 between UC and time in a mixed-effects model adjusted for the factors mentioned
4 above. A random intercept for each patient accounted for repeated measures across
5 days. The mean expected excess weights of patients with and without UC was
6 calculated assuming mean values for continuous predictors and a proportion of
7 positive categorical predictors similar to the study sample.
8
9
10
11
12
13
14
15
16
17
18
19
20

21 *Clinical improvements and complications*

22
23
24 The unadjusted impact of UC on time-dependent outcomes was analysed using
25 Kaplan–Meier survival analysis and an unweighted, two-sided, log-rank test to
26 compare groups. Analysis of target weight was restricted to patients with volume
27 overload. Analyses of intravenous diuretics, oxygen supply and CPAP were restricted
28 to patients receiving those therapies. Multivariate Cox models were adjusted for age,
29 sex and Charlson comorbidity index score. For target weight and the time needed to
30 discontinue intravenous diuretics, Cox models were further adjusted for all the
31 confounding factors in the primary analysis. The proportional hazards assumption was
32 verified using Schoenfeld residuals and a visual inspection of the log-minus-log plots
33 (Statistics S3).
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

50 The association between UC and LOS was tested using a linear regression model
51 adjusted for confounding factors and in which LOS was log-transformed to correct for
52 skewed data. Logistic regression was used to adjust binary outcomes for
53 confounders. Comparisons of characteristics between groups were performed using
54 the chi-squared test or Fisher's exact test, where appropriate, for categorical
55
56
57
58
59
60

1 variables. The Mann–Whitney test was used for continuous variables as these were
2
3 not normally distributed. Except for the primary outcomes, all analyses were two-
4
5 sided, with a significance level set at 5%. All analyses were performed using STATA,
6
7 version 12.0, and R statistical software, Version 4.0.0.^[23]
8
9

10 11 12 13 14 15 **RESULTS**

16
17
18
19 Of 640 potential participants in the HF register, 174 had no available paper medical
20
21 chart and 7 had had no diuretic therapy within the first 7 days, leaving a cohort of 459
22
23 patients of whom 113 underwent UC within the first 24 h (24.6%). Only four of these
24
25 patients had documented urinary retention. Catheterised patients were older, more
26
27 often women, more frequently experienced respiratory failure or AKI, and received
28
29 higher initial diuretic doses (**Table 1**). Urinary catheters were placed for a median of 4
30
31 days (IQR: 2–8). Diuresis was recorded more often among patients with UC (58.0%)
32
33 than patients without (41.2%, $p < 0.01$).
34
35
36
37
38
39
40
41

42 **EXCESS WEIGHT UNDER DIURETIC THERAPY**

43
44
45 At diuretic therapy initiation, 342 patients carried excess weight and were included in
46
47 the primary analysis (Figure S1). In adjusted linear regressions, being catheterised
48
49 was not associated with significantly greater 48 h weight loss than not being
50
51 catheterised (0.43 Kg in favour of UC (95% CI: -0.03–0.88)). The upper confidence
52
53 interval of between-group difference was below the non-inferiority boundary of 1 kg (p
54
55 < 0.01 for non-inferiority).
56
57
58
59
60

1 In sensitivity analysis, the results were in line with the primary analysis (Table S2). In
2
3 the propensity score-matched analysis, 64 patients with UC were matched with 64
4
5 patients without a catheter (none had urinary retention). The difference in weight loss
6
7 was 0.29 kg (95% CI: -0.3–0.88; $p < 0.01$ for non-inferiority).
8
9

10
11
12
13
14
15 Patients with UC did not have a statistically lower persistent excess weight at 72 h: the
16
17 difference was 0.27 kg (95% CI: -0.52–1.1; $p = 0.50$) in unadjusted and 0.24 kg
18
19 (95% CI: -0.17–0.64; $p < 0.001$ for non-inferiority) in adjusted linear regression. At one
20
21 week, the excess weight difference between patients with and without UC was -0.09 kg
22
23 (95% CI: -1.0–0.8; $p = 0.84$) in unadjusted and -0.14 kg (95% CI: -0.89–0.60; $p = 0.01$
24
25 for non-inferiority) in adjusted linear regression. Similarly, there was no statistically
26
27 significant interaction between UC and daily excess weight changes in the mixed-
28
29 effects model ($p = 0.55$; **Figure 1**).
30
31
32
33
34
35
36
37

38 **CLINICAL IMPROVEMENT**

39
40
41 Time to reach target weight and time needed to discontinue CPAP were not statistically
42
43 different between patients with and without UC in both unadjusted and adjusted
44
45 analysis (**Figure 2, Table 2**). UC tended to be associated with a longer time to
46
47 discontinuation of an intravenous diuretic or discontinuation of oxygen supply (**Figure**
48
49 **2**), but the associations disappeared after adjustment for confounders (**Table 2**).
50
51
52
53
54
55
56
57
58
59
60

1 The median hospital LOS was identical for patients with and without UC (12 days, IQR:
2 9–18). However, fewer UC patients were discharged directly home from hospital
3
4 (57.3% vs 73.7%; adjusted OR 0.6 (95% CI: 0.3–0.9; $p < 0.01$)).
5
6
7
8
9
10

11 12 **COMPLICATIONS**

13
14
15 The proportions of initial treatment failures, low blood pressure episodes and patients
16 with worsening kidney function were not statistically different between groups (**Table**
17
18 **2**).
19
20
21
22
23
24
25
26

27 All-cause and HF-related readmissions were not statistically different between patients
28 with and without UC (**Table 2** and **Figure 3**). Half the patients with UC and one third
29 without UC were dead at one year. The difference was not statistically significant after
30 adjustment (**Table 2**).
31
32
33
34
35
36
37
38
39

40 UC patients were at a higher risk of suffering from a UTI, and this association persisted
41 in adjusted analyses (**Table 2** and **Figure 3**). Multiple UTIs occurred in 9 UC patients
42 (8.0%) and in 5 patients without UC (1.2%, $p < 0.01$). Patients with a UTI had a longer
43 hospital LOS (15 days (IQR: 10–21) vs 11 days (IQR: 8–17), $p < 0.001$) and an
44 increased one-year mortality rate (52.5% vs 34.0%, adjusted HR 1.5; 95% CI: 1.1–2.3;
45
46
47
48
49
50
51
52 $p = 0.038$).
53
54
55
56
57

58 **DISCUSSION AND CONCLUSION**

59
60

1 Among patients admitted to medical wards for acute HF, the strategy of abstaining
2 from UC did not lead to inferior initial weight loss when compared to the strategy of UC
3 placement within the first 24 h. Besides, UC had no impact on clinical improvement
4 such as the time needed to reach target weight, discontinue intravenous diuretics or
5 improve respiratory failure, and hospital LOS. Furthermore, UC did not prevent
6 excessive diuresis resulting in low blood pressure episodes or worsening kidney
7 function, and it was associated with a higher risk of a UTI.
8
9
10
11
12
13
14
15
16
17
18
19
20

21 There are few appropriate indications for UC,^[14] and 7% to 50% of UCs are done
22 outside these indications (Table S3).^[24, 25] Rates of UC subsequent to HF vary greatly
23 and could be very high. In one study, more than half of haemodynamically stable
24 patients underwent UC.^[11] The rationale for UC in HF is weak yet somehow based on
25 beliefs that it facilitates urine elimination and increases comfort by decreasing toilet
26 visits. However, there is good evidence that UC does not increase the comfort of
27 patients undergoing diuretic therapy, even at high dosages.^[13] Most guidelines on UC
28 good practice do not list HF as a standard indication.^[26] Through their *Choosing Wisely*
29 campaigns, Swiss and American authorities recommend avoiding in-dwelling UC for
30 urine output monitoring in stable patients who can void or for patient or staff
31 convenience.^[27, 28] Indication lists, authorities' recommendations and financial
32 penalties have reduced the overall inappropriate use of UC.^[14] An American study
33 showed that the proportion of UC among HF patients decreased by 8% between 2009
34 and 2014.^[10]
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 Catheter-associated UTIs (CAUTIs) are the second most common infections
2 associated with patients hospitalised for HF after *Clostridium*-related infections.^[29]
3
4 Previous reports among HF patients found associations between CAUTI and increased
5
6 risks of discharge to a skilled care facility, longer hospital LOS, higher total hospital
7
8 costs and in-hospital mortality.^[11, 29] Condom catheters are a better option when
9
10 diuresis affects older patients with a disability: they lead to fewer complications,^[30] are
11
12 more comfortable and are less painful than UC.^[13]
13
14
15
16
17
18
19
20

21 The present study is the first to consider association between UC and clinically relevant
22
23 outcomes in the context of HF. Using a register and significant adjustments to potential
24
25 confounding factors further strengthened our findings. However, the study has
26
27 limitations. Firstly, the cohort preceded some important advances in HF management
28
29 (e.g.: sacubitril treatment or SGLT2 inhibitors) that may have changed readmission risk
30
31 and mortality. Nevertheless, there were no changes in the 2021 ESC guidelines
32
33 concerning the management of acute HF using diuretics, or the relevance of UC
34
35 insertion in this indication.^[3] We thus believe that our study's conclusions remain valid
36
37 today. Secondly, the study's retrospective, observational approach only allowed us to
38
39 hypothesise that urinary catheters were placed for HF management. To minimise these
40
41 issues, we only selected UCs which occurred in the first 24 h of diuretic therapy.
42
43 Thirdly, since patients are usually not weighed in emergency rooms, we focused on
44
45 the weight change from days 1 to day 3. Thus, UC's impact during the first 24 h of
46
47 diuretic therapy was not assessed. A randomised prospective design, with protocols to
48
49 guide rapid diuretic adaptation, would be better able to explore the UC's real potential
50
51 among HF patients. However, considering current evidence and risks, such a study
52
53 may never occur. It is of note that records of the amount of urine passed were only
54
55
56
57
58
59
60

1 available for half of the patients, with or without UC. Thus, checking for adequate
2
3 diuresis after treatment with diuretics might be a simpler, safer recommendation than
4
5 UC for improved HF management. Finally, some medical charts could not be retrieved,
6
7 but their unavailability was random and unrelated to their UC status or outcomes. Thus,
8
9 there is little risk that unavailable charts biased the results.
10
11
12
13
14
15
16

17 In this retrospective study, with no obvious hourly diuresis-based diuretic adjustment
18
19 strategy, weight loss without UC was not inferior to weight loss after UC within 24 h of
20
21 initiating diuretic treatment. UC had no impact on the clinically relevant outcomes of
22
23 time to reach target weight, time to resolve respiratory failure and hospital LOS. The
24
25 lack of benefits and the increased risk of a UTI preclude systematic UC for the
26
27 management of HF.
28
29
30
31

32 **DATA AVAILABILITY**

33
34
35
36 The database, variable explanation, and Stata do-file (in Word format) are available at
37
38 request to gregor.john@rhne.ch.
39
40
41
42
43
44
45

46 **REFERENCES**

- 47
48 1. Savarese G, Lund LH. Global Public Health Burden of Heart Failure. *Card Fail Rev.* **3**, 7-11 (2017).
- 49
50 2. Barasa A, Schaufelberger M, Lappas G, Swedberg K, Dellborg M, Rosengren A. Heart failure in young
51
52 adults: 20-year trends in hospitalization, aetiology, and case fatality in Sweden. *Eur Heart J.* **35**,
53
54 25-32 (2014).
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
3. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J.* **36**, 3599-726 (2021).
4. Benjamin, E. J. *et al.* Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. *Circulation.* **139**, e56-e528 (2019).
5. Jessup, M. *et al.* 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. *Circulation.* **119**, 1977-2016 (2009).
6. McMurray, J. J. *et al.* ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. *Eur Heart J.* **33**, 1787-847 (2012).
7. Felker, G. M. *et al.* Diuretic strategies in patients with acute decompensated heart failure. *N Engl J Med.* **364**, 797-805 (2011).
8. Felker, G. M., O'Connor, C. M., Braunwald, E. Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil? *Circ Heart Fail.* **2**, 56-62 (2009).
9. ter Maaten JM, et al. Diuretic response in acute heart failure-an analysis from ASCEND-HF. *Am Heart J.* **170**, 313-21 (2015).
10. Metersky, M. L. *et al.* National trends in the frequency of bladder catheterization and physician-diagnosed catheter-associated urinary tract infections: Results from the Medicare Patient Safety Monitoring System. *Am J Infect Control.* **45**, 901-04 (2017).

- 1 11. Jang, A. Y. *et al.* Routine Indwelling Urethral Catheterization in Acute Heart Failure Patients
2
3
4 Is Associated With Increased Urinary Tract Complications Without Improved Heart
5
6 Failure Outcomes. *Circ J.* **82**, 1632-39 (2018).
7
- 8 12. Aoki, T. Appropriate Use of Urinary Catheter in Acute Heart Failure Patients. *Circ J.* **82**,
9
10 1505-06 (2018).
11
- 12 13. Saint, S. *et al.* Condom versus indwelling urinary catheters: a randomized trial. *J Am Geriatr*
13
14 *Soc.* **54**, 1055-61 (2006).
15
- 16 14. Meddings, J. *et al.* Reducing unnecessary urinary catheter use and other strategies to
17
18 prevent catheter-associated urinary tract infection: an integrative review. *BMJ Qual*
19
20 *Saf.* **23**, 277-89 (2014).
21
22
- 23 15. Hollingsworth, J. M. *et al.* Determining the noninfectious complications of indwelling
24
25 urethral catheters: a systematic review and meta-analysis. *Ann Intern Med.* **159**, 401-
26
27 10 (2013).
28
29
- 30 16. Garin, N. *et al.* Inclusion into a heart failure critical pathway reduces the risk of death or
31
32 readmission after hospital discharge. *Eur J Intern Med.* **23**, 760-4 (2012).
33
34
- 35 17. Berra, G. *et al.* Outcome in acute heart failure: prognostic value of acute kidney injury and
36
37 worsening renal function. *J Card Fail.* **21**, 382-90 (2015).
38
39
- 40 18. Anisman SD, Erickson SB, Morden NE. How to prescribe loop diuretics in oedema. *BMJ.*
41
42 **364**; l359 (2019).
43
44
- 45 19. Sundararajan, V. *et al.* New ICD-10 version of the Charlson comorbidity index predicted in-
46
47 hospital mortality. *J Clin Epidemiol.* **57**, 1288-94 (2004).
48
49
- 50 20. Shah RV, McNulty S, O'Connor CM, Felker GM, Braunwald E, Givertz MM. Effect of admission oral
51
52 diuretic dose on response to continuous versus bolus intravenous diuretics in acute heart
53
54 failure: an analysis from diuretic optimization strategies in acute heart failure. *Am Heart J.* **164**,
55
56 862-8 (2012).
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
21. Voors AA, et al. Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome--an analysis from RELAX-AHF. *Eur J Heart Fail*. **16**, 1230-40 (2014).
 22. Ezekowitz JA, O'Meara E, McDonald MA, Abrams H, Chan M, Ducharme A, et al. 2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. *Can J Cardiol*. **33**, 1342-433 (2017).
 23. R Core Team (2017). R: A language and environment for statistical computing. [program], 2019. R Foundation for Statistical Computing, Vienna, Austria. URL <https://www.R-project.org/>.
 24. Saint, S. *et al*. Are physicians aware of which of their patients have indwelling urinary catheters? *Am J Med*. **109**, 476-80 (2000).
 25. Gokula, R. R., Hickner, J. A., Smith, M. A. Inappropriate use of urinary catheters in elderly patients at a midwestern community teaching hospital. *Am J Infect Control*. **32**, 196-9 (2004).
 26. Centers for Disease Control and Prevention. Examples of Appropriate Indications for Indwelling Urethral Catheter Use. URL: <https://www.cdc.gov/infectioncontrol/guidelines/cauti/recommendations.html> (last access: 09.04.2020)
 27. Physicians ACoE. Choosing Wisely, 2013. URL: <https://www.choosingwisely.org/societies/american-college-of-emergency-physicians/> (last access: 09.04.2020)
 28. Générale SSdmi. Choosing Wisely, 2016. URL: <https://www.smartermedicine.ch/fr/liste-top-5/infektiologie.html#c15766> (last access: 09.04.2020)
 29. Miller, P. E. *et al*. National Trends in Healthcare-Associated Infections for Five Common Cardiovascular Conditions. *Am J Cardiol*. **124**, 1140-48 (2019).

1 30. Saint, S. *et al.* Condom Catheters versus Indwelling Urethral Catheters in Men: A
2
3
4 Prospective, Observational Study. *J Hosp Med.* **14**, E1-E4 (2019).
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

ACKNOWLEDGEMENTS

Contributor: We gratefully acknowledge Elise Dupuis for her help with the statistical analysis.

Funders: The study received a grant from Geneva University Hospitals (grant: PRD 1-2017-I).

ETHICAL STATEMENT

The institutional review board of Geneva university hospital
Comission cantonale d'éthique de la recherche (CCER): 08-250R

AUTHORS CONTRIBUTIONS

G.J., S.C., N.G., D.C. and J.S.: planned the study (protocol). **M.A. and G.B.** collected the data. **G.J. and J.S.** performed the analyses. **G.J.** wrote the manuscript. All authors reviewed and approved the final manuscript.

CONFLICT OF INTEREST STATEMENT

The authors declare no competing interests.

ABBREVIATIONS

AKI: acute kidney injury

1 CI: confidence interval

2
3 CPAP: continuous positive airway pressure HF: heart failure

4
5 HR: hazard ratio

6
7
8
9
10 KDIGO: Kidney Disease: Improving Global Outcomes

11
12 LVEF: left ventricular ejection fraction

13
14 OR: odds ratio

15
16 UC: urinary catheterisation

17
18 UTI: urinary tract infection

19 20 21 22 23 24 25 **ONLINE SUPPLEMENTS**

26
27
28
29 **Statistic S1:** Choice of non-inferiority boundary and sample size calculation

30
31 **Statistic S2:** Sensitivity analysis

32
33 **Statistic S3:** Proportional assumption and test

34
35
36 **Table S1:** Choice of adjustment variable

37
38 **Table S2:** Sensitivity analysis results

39
40
41 **Table S3:** List of indications for urinary catheter insertion per the Swiss 'Progress! Safe
42 urinary catheterization' programme

43
44
45 **Figure S1:** Study flow-chart

1
2
3
4 **Figure 1:** Predicted excess weight (kg) over time (days) for patients with (black line) and
5 without (green line) urinary catheterisation (UC). Mean expected excess weights and their
6 confidence intervals were calculated using an adjusted mixed-effects model assuming mean
7 values for continuous predictors and a proportion of positive categorical predictors similar to
8 the study sample. UC had no statistical effect on excess weight evolution over time (p for
9 interaction = 0.55).
10
11
12
13
14
15
16
17
18
19
20
21
22
23

24 **Figure 2:** Time to reach clinical improvement for patients with urinary catheterisation (black
25 line) and controls (green line): (A) time to reach target weight; (B) time to discontinuation of
26 intravenous diuretics; (C) time to discontinuation of continuous positive airway pressure
27 therapy; and (D) time to discontinuation of oxygen supply.
28
29
30
31
32
33
34
35
36
37
38
39
40

41 **Figure 3:** Time to reach unfavourable outcomes for patients with urinary catheterisation (black
42 line) and controls (green line): (A) time to first urinary tract infection; (B) time to first all-cause
43 hospital readmission; (C) time to first heart failure-related readmission; and (D) time to death.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1: Characteristics of participants with and without urinary catheterisation (UC). Only UC within 24 h of diuretic therapy initiation was considered. Values are numbers (percentage) unless otherwise stated.

Characteristic	Cohort (N = 459)	With UC (N = 113)	Without UC N = 346)	P value
Age (y), median (IQR)	81 (73–86)	83.5 (76–89)	80 (71–85)	< 0.001
Male	248 (55.2%)	52 (47.3%)	196 (57.8%)	0.053
Admitted through ER	398 (86.7%)	97 (85.8%)	301 (87.0%)	0.754
Night-time admission (19h00–07h00)	169 (36.8%)	37 (32.7%)	132 (38.1%)	0.301
Current smoker	79 (18.0%)	18 (17.3%)	61 (18.1%)	0.844*
High blood pressure	331 (73.7%)	83 (73.7%)	248 (73.2%)	0.709
Diabetes	135 (30.1%)	34 (30.9%)	101 (29.8%)	0.812
Myocardial infarct	27 (6.1%)	6 (5.5%)	21 (6.3%)	0.762*
LVEF<50%	203 (45.2%)	46 (40.7%)	157 (45.4%)	0.686
Stroke	52 (11.8%)	18 (16.1%)	34 (10.2%)	0.076*
Peripheral vascular disease	76 (17.2%)	23 (21.1%)	53 (15.9%)	0.242*
Dementia	30 (6.8%)	9 (8.3%)	21 (6.3%)	0.482*
COPD	66 (14.7%)	16 (14.5%)	50 (14.7%)	0.958*
Oncological disease	32 (7.2%)	8 (7.3%)	24 (7.2%)	0.963*
Liver disease	24 (5.4%)	7 (6.4%)	17 (5.1%)	0.598*
CKD				
II	174 (38.7%)	39 (35.4%)	135 (39.2%)	0.380
III	154 (34.4%)	40 (36.4%)	114 (33.6%)	
IV	22 (4.9%)	6 (5.5%)	16 (4.7%)	
V	2 (0.5%)	0	2 (0.6%)	
Charlson comorbidity index, median (IQR)	3 (1–4)	3 (2–4)	3 (1–4)	0.115
Pre-admission medication				
ACE/ARB	290 (64.6%)	65 (59.1%)	225 (66.4%)	0.165
Beta-blocker	204 (45.4%)	49 (44.5%)	155 (45.7%)	0.829
Aldosterone inhibitor	62 (13.8%)	14 (12.7%)	48 (14.2%)	0.753*
Diuretics	239 (52.1%)	66 (58.4%)	173 (50.0%)	0.120
Admission characteristics				
Median sodium level (mmol/l) at admission (IQR)	137 (134–140)	137 (133–139)	138 (135–140)	0.022
Median NT-proBNP level (ng/l) at admission (IQR)	6377 (3069–13254)	7700 (4080–16204)	6206 (2700–12101)	0.124
Median haemoglobin level (g/l) at admission (IQR)	123 (109–137)	119 (107–133)	125 (110–138)	0.115
Median creatinin level (mmol/l) at admission (IQR)	107 (85–148)	116 (89–197)	104 (83–138)	0.005
Heart rate (beat/min), median (IQR)	81 (70–94)	82.5 (70–91)	80 (69.5–95)	0.785
Mean blood pressure (mmHg), median (IQR)	90 (80–100)	88.3 (78.3–100)	90 (80.3–100)	0.162
AKI				
I	143 (31.5%)	46 (41.8%)	97 (28.6%)	0.002*
II	24 (5.3%)	9 (8.2%)	15 (4.4%)	
III	5 (1.1%)	3 (2.7%)	2 (0.6%)	
Respiratory failure:	371 (80.8%)	105 (92.9%)	266 (76.9%)	< 0.001*
- Needs oxygen supply	365 (79.5%)	104 (92.0%)	261 (75.4%)	
- CPAP	75 (16.3%)	27 (23.9%)	48 (13.9%)	
Volume overload	342 (74.5%)	86 (76.1%)	256 (74.0%)	0.654
- Target weight (kg), median (IQR)	69.2 (58.1–80.8)	70 (58–81.4)	68.7 (58.6–80.5)	
Intravenous therapy	431 (93.9%)	108 (95.6%)	323 (93.4%)	0.391*
Continuous intravenous diuretic therapy	42 (9.2%)	15 (13.4%)	27 (7.8%)	0.076*

Initial diuretic doses (mg), median (IQR)	40 (30–80)	60 (40–90)	40 (20–60)	< 0.001
* Fischer test ACE, angiotensin-converting-enzyme inhibitor; AKI, acute kidney injury; ARB, angiotensin receptor blockers; CKD, chronic kidney disease by CKD-EPI classification; COPD, chronic obstructive pulmonary disease; CPAP, continuous positive airway pressure therapy; ER, emergency room; LVEF: left ventricular ejection fraction; UC: urinary catheterisation				


For peer review only

Table 2: Clinical improvements and adverse outcomes with and without urinary catheterisation. Values are numbers unless otherwise stated.

Time to clinical improvement	With UC	Without UC	HR	Adjusted HR*
Time to target weight (d), median (IQR)	6 (3–7)	6 (3–7)	1.1 (0.8–1.5)	1.0 (0.7–1.5)
Time to switch/discontinuation of intravenous diuretics (d), median (IQR)	4 (2–8)	3 (1–6)	0.8 (0.7–1.0)	0.9 (0.7–1.2)
Time to discontinuation of CPAP (d), median (IQR)	4 (2–6)	4 (2–5)	1.2 (0.7–2.2)	1.1 (0.5–2.4)
Time to discontinuation of oxygen supply (d), median (IQR)	4 (2–8)	3 (1–7)	0.8 (0.6–1.0)	0.9 (0.7–1.2)
Time to adverse events	With UC	Without UC	HR	Adjusted HR†
Urinary tract infection, n (%)	37 (32.7%)	46 (13.3%)	2.9 (1.8–4.8)‡	2.5 (1.5–4.2)‡
One-year all-cause hospital readmission, n (%)	56 (50.9%)	193 (56.9%)	1.1 (0.8–1.4)	1.1 (0.8–1.4)
One-year heart failure-related hospital readmission, n (%)	28 (25.5%)	91 (26.8%)	1.1 (0.7–1.7)	1.1 (0.7–1.7)
One-year mortality, n (%)	51 (50.0%)	101 (33.4%)	1.7 (1.2–2.4)‡	1.4 (1.0–2.1)
Other secondary outcomes	With UC	Without UC	OR	Adjusted OR†
Initial treatment failure	23 (26.7%)	78 (30.5%)	0.8 (0.5–1.4)	0.8 (0.4–1.4)
Low blood pressure episode	49 (43.7%)	154 (44.6%)	1.0 (0.6–1.5)	1.1 (0.7–1.7)
- Need of saline perfusion	24/49 (49.0)	67/154 (43.5)		
Worsening of renal function				
0	82 (74.6%)	260 (76.7%)	1.1 (0.7–1.8)¶	1.1 (0.7–1.8)¶
1	27 (24.6%)	73 (21.5%)		
2	1 (-)	6 (1.8%)		
<p>* Models were adjusted for age (continuous), sex (binary), Charlson index score (continuous), pre-admission diuretic dose (continuous), HF type (categorical), admission heart rate and blood pressure (continuous), respiratory failure (binary), weight excess at diuretic therapy (continuous), first diuretic dose (continuous), use of continuous intravenous diuretics (binary), AKI (categorical) and admission through the emergency room (binary); † Models were adjusted for age (continuous), sex (binary), Charlson index score (continuous); ‡ p value < 0.05; ¶ OR of changing to a worse category;</p> <p>CPAP, continuous positive airway pressure therapy; UC, urinary catheterisation</p>				


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only




Predicted excess weight (kg) over time (days) for patients with (black line) and without (green line) urinary catheterisation (UC). Mean expected excess weights and their confidence intervals were calculated using an adjusted mixed-effects model assuming mean values for continuous predictors and a proportion of positive categorical predictors similar to the study sample. UC had no statistical effect on excess weight evolution over time (p for interaction = 0.55).

296x209mm (150 x 150 DPI)



Time to reach clinical improvement for patients with urinary catheterisation (black line) and controls (green line): (A) time to reach target weight; (B) time to discontinuation of intravenous diuretics; (C) time to discontinuation of continuous positive airway pressure supply; and (D) time to discontinuation of oxygen supply.

244x178mm (72 x 72 DPI)



Time to reach unfavourable outcomes for patients with urinary catheterisation (black line) and controls (green line): (A) time to first urinary tract infection; (B) time to first all-cause hospital readmission; (C) time to first heart failure-related readmission; and (D) time to death.

244x178mm (72 x 72 DPI)

Risks and benefits of urinary catheterisation during inpatient diuretic therapy for acute heart failure: A retrospective, non-inferiority, cohort study

G John, M Arcens, G Berra, N Garin, D Carballo, S Carballo, J Stirnemann

Supplemental Materials

Statistic S1: Choice of non-inferiority boundary and sample size calculation	p 2
Table S1: Choice of adjustment variable	p 3-4
Statistic S2: Sensitivity analysis	p 5
Table S2: Sensitivity analysis results	p 6
Figure S1: Study flow-chart	p 7
Table S3: List of indications for urinary catheter insertion per the Swiss 'Progress! Safe urinary catheterization' programme	p 8
Statistic S3: Proportional assumption and test	p 9-18
<i>Table S4:</i> Schoenfeld residuals test in multivariable Cox regression	p 8
<i>Table S5:</i> Sensitive analysis for the model on time to reach target weight and CPAP, including time-varying covariates.	p 9
<i>Figure S2:</i> Proportional hazard assumption and analysis	p 11
<i>Figure S3:</i> Schoenfeld residuals plots over Time for urinary catheterisation (UC) and covariates in the model for time to reach target weight	p 12
<i>Figure S4:</i> Schoenfeld residuals plots over Time for urinary catheterisation (UC) and covariates in the model for time to discontinue intravenous diuretic therapy.	p 13
<i>Figure S5:</i> Schoenfeld residuals plots over Time for urinary catheterisation (UC) and covariates in the model for time to discontinue CPAP	p 14
<i>Figure S6:</i> Schoenfeld residuals plots over Time for urinary catheterisation (UC) and covariates in the model for time until oxygen supply discontinuation	p 15
<i>Figure S7:</i> Schoenfeld residuals plots over Time for urinary catheterisation (UC) and covariates in the model for time to death	p 16
<i>Figure S8:</i> Schoenfeld residuals plots over Time for urinary catheterisation (UC) and covariates in the model for time to first urinary tract infection.	p 16
<i>Figure S9:</i> Schoenfeld residuals plots over Time for urinary catheterisation (UC) and covariates in the model for time to first hospital readmission	p 17
References	p 19

Statistic S1: Choice of non-inferiority boundary and sample size calculation

The non-inferiority cut-off was based on daily minimal weight loss under diuretic therapy of 500 grams (=1Kg in 2 days), acknowledge by guidelines on HF management.^[1] Thus, a therapy achieving less than this target of weight loss would be considerate to have no or only minimal effect and would be increased (or changed). Similarly, two treatments resulting in weight loss difference under this minimal daily significant weight loss would be considerate to have “no clinically relevant difference”.

The sample size was calculated based on an expected mean weight loss during the first days of 4.2 litters (SD 3.2) under diuretic therapy ^[2], and a clinically relevant difference of 1 litter between groups (for the UC group). This resulted in 376 patients (one third with an UC) needed to demonstrate non-inferiority with a one-sided significant level of 0.05 and a power of 90%.

For peer review only

Table S1: The variables associated with diuretics effectiveness in three studies (ASCEND-HF; RELAX-AHF; DOSE-AHF) compared to the variables included as adjustments in the multivariable models of our study.

Factors		Studies			
Category	Variable	ASCEND-HF [6]	RELAX-AHF [7]	DOSE-AHF [8]	Our study ¹
Diuretics	Home loop diuretics	Home loop diuretics (chronic use) use	-	Home loop diuretics (dose)	Home loop diuretics (dose) use
	Continuous vs intermittent	-	-	Type of therapy (continuous vs intermittent)	Type of therapy (continuous vs intermittent)
	Initial IV diuretic dose	Loop diuretic	-	Initial IV diuretic dose	Initial IV diuretic dose
	Bumetanide use	Bumetanide use	-	-	NA ²
General characteristics	Sex	Female sex	-	-	Female sex
	Age	-	-	-	Age
	Ethnicity	Ethnicity	Ethnicity	-	NA ³
Weight and oedema	Oedema	Oedema	Oedema	-	NA ⁴
	Baseline weight	Baseline weight	Baseline weight	Baseline weight	Baseline weight
Vital signs/ Haemodynamics	Blood pressure	Systolic and diastolic blood pressure	Diastolic blood pressure	-	Systolic blood pressure
	Heart rate	-	-	-	Heart rate
	Body temperature	-	Body temperature	-	NA
	Respiratory rate	-	Respiratory rate	-	Respiratory failure (hypoxemia and/or non-invasive respiratory therapy)
Heart failure severity	Dyspnoea	Orthopnoea	Dyspnoea	-	(hypoxemia and/or non-invasive respiratory therapy)
	HF hospitalisation last year	-	HF hospitalisation last year	-	NA
	NT-proBNP	-	NT-proBNP (median vs < median)	-	Not included
	LVEF	-	LVEF (no effect)	-	LVEF (> 50% vs < 50% vs unknown)
	Mode of hospital admission	-	-	-	Admission through ER
	Diabetes	Diabetes	-	-	Charlson comorbidities index

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Comorbid conditions	Hyperlipidaemia	Hyperlipidaemia	-	-	
	Atrial Fibrillation	-	Atrial Fibrillation	-	
	Percutaneous intervention	-	Percutaneous intervention	-	
	Hyperthyroid	-	Hyperthyroid	-	
Laboratory	Renal function	baseline (at admission) creatininemia	BUN	baseline (at admission) creatininemia	Grade of acute renal injury at admission (0–3)
	Baseline potassium	Baseline potassium	Baseline potassium	-	NA
	Baseline sodium at admission	Baseline sodium at admission	Baseline sodium at admission	-	Not included
	Uric acid	-	Uric acid	-	NA
	Aspartate aminotransferase	-	Aspartate aminotransferase	-	NA
	Total protein (g/l)	-	Total protein (g/l)	-	NA
<p>1) The model was adjusted for age (continuous), sex (binary), Charlson index score (continuous), pre-admission diuretic dose (continuous), HF type (categorical), admission heart rate and blood pressure (continuous), respiratory failure (binary), weight excess at diuretic therapy (continuous), first diuretic dose (continuous), use of continuous intravenous diuretics (binary), AKI (categorical) and admission through the emergency room (binary). Adjustment factors were chosen based on clinical expertise. To reach non-inferiority, the upper confidence interval of a between-group difference had to be less than 1 kg (in favour of UC). Unilateral T-test served to test non-inferiority; 2) No Bumetanide use during the study; 3) Database did not collect ethnicity; proportion of patients of African or Asian origin is relatively small in Geneva, most being Caucasian; 4) Although the presence of oedema was not collected in the database, the analysis of diuretic responsiveness was restricted to patients with weight excess (compared to their target weight) and thus most of them would have had oedema. NA: not assessed (not collected during the study)</p>					

1
2
3 **Statistic S2:** Sensitive analyses:
4

5 We performed several sensitivity analyses for the main outcome. Firstly, multiple imputation method
6 was used to replace missing values. Missing data, which were all 5% or less, were inspected to ensure
7 that the missing at random assumption was reasonable. Imputation involved all baseline responders
8 and utilised the variables in the adjusted models. Missing data were imputed using chained equations.
9 Twenty imputed datasets were generated and parameter estimates were combined using Rubin's
10 rules. The second sensitivity analysis excluded patients with urinary retention. The third matched
11 catheterised patients 1:1 to non-catheterised patients according to sex and the closest value (< 10%)
12 of a propensity score. The score included all the variables mentioned above except sex. A paired t-test
13 was used to test mean differences.
14
15

16 The fourth replaced AKI at admission by creatininemia and blood sodium. In the last analysis the
17 continuous confounding variables were split in the median (results in **Table S2**).
18
19

20
21 It could be hypothesized that the "no difference" observed in the time to reach target weight could
22 come from a wrong estimation of the weight to "target". Patients could die before to reach their
23 "true" target weight, and the lowest weight (close to death) would be retained as the "study target
24 weight". We decided to add a sensitive analysis, excluding patients that died within the first week of
25 hospital admission, or patients that attain the target weight less than 5 days before to die (16
26 patients in total). The results of this sensitive analysis was in line with the main result: adjusted HR for
27 time to reach target weight was 0.97 (95%CI: 0.64-1.44, p=0.87).
28
29
30

31
32 For readmission and mortality, we performed one sensitivity analysis adding haemoglobin and
33 natremia at admission, chronic renal function, LVEF, and systolic blood pressur to age, comorbidities
34 and sex. [3,4] The adjusted hazard ratios for one-year readmission and one-year mortality were 1.02
35 (95% CI: 0.65–1.61; p = 0.93) and 1.27 (95% CI: 0.87–1.86; p = 0.22), respectively. The difference was
36 not statistically significant and comforted the analyses in the main manuscript.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table S2: Sensitive analysis for the main outcome. Numbers are coefficient of the linear regression (95%CI).

	Model 1	Model 2	Model 3	Model 4	Model 5
Urinary catheter	0.43 (-0.03-0.88)*	0.42 (-0.04-0.88)*	0.43 (-0.03-0.87)*	0.38 (-0.08-0.83)*	0.36 (-0.08-0.80)*
age	-0.01 (-0.02-0.01)	-0.06 (-0.02-0.01)	-0.23 (-0.60-0.15)	-0.05 (-0.02-0.01)	-0.01 (-0.02-0.01)
sex	-0.32 (-0.73-0.08)	-0.32 (-0.73-0.08)	-0.35 (-0.76-0.07)	-0.39 (-0.81-0.02)	-0.35 (-0.74-0.03)
Charlson index	0.04 (-0.07-0.14)	0.04 (-0.06-0.14)	-0.01 (-0.41-0.38)	0.04 (-0.07-0.14)	0.02 (-0.08-0.12)
Chronic diuretic dose	-0.003 (-0.008-0.003)	-0.002 (-0.008-0.003)	0.16 (-0.22-0.55)	-0.002 (-0.007-0.004)	-0.003 (-0.007-0.003)
LVEF<50% (vs LVEF>50%)	-0.32 (-0.76-0.11)	-0.31 (-0.75-0.13)	-0.29 (-0.73-0.15)	-0.33 (-0.77-0.11)	-0.31 (-0.73-0.11)
Unassessed FEVG	-0.23 (-0.67-0.29)	-0.25 (-0.75-0.25)	-0.26 (-0.76-0.24)	-0.27 (-0.76-0.23)	-0.25 (-0.74-0.23)
admission heart rate	0.005 (-0.005-0.015)	0.005 (-0.005-0.015)	0.10 (-0.28-0.48)	0.004 (-0.006-0.014)	0.005 (-0.005-0.015)
Systolic blood pressure	0.006 (-0.002-0.015)	0.006 (-0.002-0.015)	0.09 (-0.28-0.45)	0.007 (-0.001-0.016)	0.005 (-0.004-0.013)
respiratory failure	-0.19 (-0.67-0.29)	-0.19 (-0.67-0.29)	-0.12 (-0.60-0.37)	-0.19 (-0.67-0.30)	-0.12 (-0.58-0.35)
weight excess at diuretic therapy	0.18 (0.12-0.24)	0.18 (0.12-0.24)	1.09 (0.71-1.47)	0.18 (0.12-0.24)	0.18 (0.12-0.23)
first diuretic dose	0.001 (-0.004-0.004)	0.001 (-0.004-0.004)	-0.18 (-0.62-0.25)	0.001 (-0.003-0.005)	0.001 (-0.003-0.004)
use of continuous intravenous diuretics	0.20 (-0.41-0.80)	0.19 (-0.41-0.79)	0.16 (-0.45-0.77)	0.05 (-0.55-0.64)	0.09 (-0.48-0.68)
AKI 1	-0.51 (-0.91-0.10)	-0.55 (-0.95-0.14)	-0.59 (-0.99-0.18)	-	-0.50 (-0.89-0.11)
AKI 2	-0.83 (-1.76-0.09)	-0.85 (-1.77-0.08)	-0.82 (-1.72-0.07)	-	-0.69 (-1.62-0.23)
AKI 3	-1.40 (-3.0-0.22)	-0.74 (-2.6-1.09)	-1.20 (-2.83-0.42)	-	-1.35 (-2.9-0.20)
admission through the emergency room	-0.02 (-0.58-0.54)	-0.001 (-0.56-0.56)	0.16 (-0.39-0.71)	-0.08 (-0.64-0.48)	0.02 (-0.51-0.56)
Admission blood sodium	-	-	-	-0.03 (-0.01-0.06)	-
Admission creatininemia	-	-	-	-0.003 (-0.005--0.0005)	-

*p value for non-inferiority <0.05

Model 1: main analysis diuretic chronic dose, diuretic first admission dose, age, Charlson index, systolic blood pressure, heart rate, weight excess at diuretic therapy as continuous variables in the model; **Model 2:** same as Model 1, but excluding the patients with urinary retention; **Model 3:** Continuous variables dichotomized (less vs mediane or more); **Model 4:** same as Model 1 but, admission blood sodium (continuous) and creatininemia (continuous) instead of AKI; **Model 5:** same as Model 1 but with multiple imputation of missing values.

AKI: acute kidney injury; LVEF: Left ventricular ejection fraction




Figure S1: Study flow-chart. D=days; H = hours; CPAP= continuous positive pressure

Table S3: List of indications for urinary catheter insertion per the Swiss 'Progress! Safe urinary catheterization' programme, adapted with permission from A. Schweiger et al. / Journal of Hospital Infection 106 (2020) 364e371 [9]

Indication	Specification	Examples
Urinary retention	<ul style="list-style-type: none"> _ Acute urinary retention regardless of aetiology _ Symptomatic chronic outlet obstruction plus >300 mL residual urine 	<ul style="list-style-type: none"> _ Benign hyperplasia of prostate gland, urethral strictures, bladderstones _ Drug induced (anticholinergics, opioids, antidepressants)
Measurement of urine volume/fluid balance	<ul style="list-style-type: none"> _ At regular intervals (hourly or as defined by hospitals) plus direct consequence on treatment of patients _ Fluid balance if patient weight not measurable on a daily basis 	<ul style="list-style-type: none"> _ Haemodynamic instability, severe rhabdomyolysis _ Coma, sedated and ventilated patient
Surgery	<ul style="list-style-type: none"> _ Long surgery (>4 h) _ Peri-interventional: need for empty bladder during surgery, removal of catheter after surgery necessary if no other indication present _ Surgery in urogenital or pelvic floor region _ Epidural/peridural anaesthesia 	
Pressure ulcers plus urinary incontinence	<ul style="list-style-type: none"> _ Stage III or IV pressure ulcers or skin transplants in sacral/ perineal region plus urinary incontinence after exhaustion of alternative strategies for urinary management 	
Prolonged immobilization	<ul style="list-style-type: none"> _ Immobilization for medical reasons, especially for pain management, after exhaustion of alternative strategies for urinary management 	<ul style="list-style-type: none"> _ Acute fractures with severe pain due to patient movement (pelvic fractures, fracture of the neck of the femur) _ Haemodynamic instability possibly caused by movement of the patient _ Transient immobility after specific interventions
Palliative care plus comfort	<ul style="list-style-type: none"> _ Palliative care plus abnormal bladder function plus/or inability for regular voiding after exhaustion of alternative strategies for urinary management _ High burden of suffering plus wish of informed patient (or relatives) 	

1
2
3 **Statistic S3:** Proportional hazard assumption for univariate and multivariate models:
4

5 The log-minus-log plots are shown in the *Figure S2* for all the **univariate association** between “urinary
6 catheter” and time to event analyses (target weight, discontinuation of intravenous diuretic therapy,
7 discontinuous of CPAP therapy, discontinuation of oxygen supply, time to hospital readmission, time
8 to first urinary tract infection, and time to death. We also performed the Schoenfeld residuals test and
9 tested the interaction between “urinary catheter” and Time in a time-varying covariate cox model. For
10 both test, proportional assumption is plausible when the p value is more than 0.05. We added the
11 results of the test in each individual graphs. Based on the three tests, proportional assumption
12 seemed to be reasonable for all the univariate cox regressions.
13

14
15 The slopes of the Schoenfeld residuals and p values of all covariates for the seven models can be
16 found in *Table S4*. For the test, a p value of <0.05 excludes proportional hazard assumption. Because
17 appreciation of the proportional assumption on the test only can be difficult, we also provided
18 Schoenfeld residuals plots with their fitted line for all the models, and all the covariates (*Figure S3-9*).
19

20
21 Urinary catheter showed proportional hazard in all the **multivariable models**. However, in the model
22 on time to target-weight, three covariates violated the proportional hazard assumption (weight excess
23 at beginning of diuretic therapy, reduced left ventricular ejection fraction, and continuous intravenous
24 therapy). Since, these variables were only used for adjustment, and the association between main
25 variable (urinary catheter and time to reach target weight) were not statistically significant in
26 unadjusted and adjusted analysis, we left these adjusting variables unchanged in the model assuming
27 a mean effect over time of these variables as proposed by Allison.^[5] Nevertheless, we also performed
28 a sensitivity analysis taking into account the time variation effect of the 3 variables in a time-varying
29 covariates Cox model, (tvc option in Stata). The model confirmed the interaction between the three
30 covariates and time ($p < 0.05$), but did not change the effect of Urinary catheter on the outcome
31 (*Table S5*).
32

33
34 For the “time to discontinue CPAP therapy” model, Charlson comorbid index score violated the
35 proportional hazard. In the time-dependant covariate model, the interaction term (time*CCI), was not
36 statistically significant (*Table S5*).
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Table S4: Proportional-hazards assumption based on Schoenfeld residuals (P value of the phtest in Stata,) and slop of the regression line (rho).

	Target weight		I.V. diuretics		CPAP		Oxygen		UTI		Readmission		Death	
	rho	P value	rho	P value	rho	P value	rho	P value	rho	P value	rho	P value	rho	P value
	0.06	0.43	0.01	0.77	0.17	0.25	0.02	0.68	0.04	0.73	0.02	0.70	-0.02	0.85
Urinary catheter	0.04	0.57	0.02	0.60	0.14	0.28	-0.002	0.97	0.09	0.44	0.02	0.69	-0.01	0.87
age	0.01	0.87	0.01	0.86	-0.16	0.27	0.04	0.45	-0.01	0.92	0.11	0.08	-0.08	0.31
sex	-0.04	0.57	-0.02	0.63	-0.15	0.28	-0.06	0.28	-0.24	0.05	-0.12	0.07	0.09	0.25
Charlson index	0.11	0.12	0.06	0.19	-0.41	0.01*	-0.02	0.69	-0.09	0.43	0.001	0.98	0.07	0.46
Chronic diuretic dose	-0.11	0.16	0.03	0.41	0.17	0.32	-0.04	0.34	-	-	-	-	-	-
LVEF<50% (vs LVEF>50%)	-0.16	0.02*	0.02	0.71	0.07	0.62	0.03	0.63	-	-	-	-	-	-
Unassessed LVEF	-0.005	0.94	0.02	0.66	0.05	0.73	0.03	0.65	-	-	-	-	-	-
admission heart rate	0.05	0.49	0.02	0.73	-0.17	0.23	0.003	0.34	-	-	-	-	-	-
Systolic blood pressure	0.01	0.87	0.10	0.05	0.26	0.06	0.06	0.95	-	-	-	-	-	-
respiratory failure	-0.06	0.40	-0.06	0.25	-	-	-	-	-	-	-	-	-	-
weight excess at diuretic therapy	0.24	0.001*	0.16	0.16	0.07	0.62	0.06	0.30	-	-	-	-	-	-
first diuretic dose	0.003	0.61	0.04	0.35	-0.22	0.12	0.02	0.76	-	-	-	-	-	-
use of continuous intravenous diuretics	-0.16	0.02*	0.09	0.08	0.09	0.61	0.01	0.84	-	-	-	-	-	-
AKI 1	-0.07	0.31	-0.02	0.70	0.13	0.37	0.10	0.10	-	-	-	-	-	-
AKI 2	0.04	0.57	0.04	0.43	-	0.98	0.04	0.53	-	-	-	-	-	-
AKI 3	-0.02	0.73	0.01	0.77	0.003	-	0.05	0.39	-	-	-	-	-	-
admission through the emergency room	-0.12	0.08	-0.04	0.42	0.07	0.61	0.08	0.17	-	-	-	-	-	-

* violation of the proportional hazard assumption (p value <0.05). AKI: acute kidney injury; CPAP: continuous positive airways pressure therapy; I.V.: intravenous; LVEF: Left ventricular ejection fraction; UTI: urinary tract infection.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table S5: Sensitive analysis for the model on time to reach target weight and CPAP, including time-varying covariates. Number are HR (95%CI)

	Time to target weight		Time to discontinue CPAP	
	Standard Cox regression model	Cox with time-varying covariates model	Standard Cox regression model,	Cox with time-varying covariates model
Urinary catheter	1.0 (0.7-1.5)	1.0 (0.7-1.4)	1.1 (0.5-2.4)	1.1 (0.5-2.3)
Age	1.0 (1.0-1.0)	1.0 (1.0-1.0)	1.0 (0.9-1.0)	1.0 (0.9-1.0)
Sex	0.7 (0.5-1.0)	0.7 (0.5-1.0)	1.4 (0.7-2.8)	1.4 (0.7-2.8)
Systolic blood pressure	1.0 (1.0-1.0)	1.0 (1.0-1.0)	1.0 (1.0-1.0)	1.0 (1.0-1.0)
Heart rate	1.0 (1.0-1.0)	1.0 (1.0-1.0)	1.0 (1.0-1.0)	1.0 (1.0-1.0)
Respiratory failure	0.9 (0.6-1.4)	0.9 (0.6-1.4)	-	-
Reduced LVEF	1.0 (0.6-1.4)	1.8 (0.9-3.6)	0.7 (0.3-1.5)	0.7 (0.3-1.5)
Severity not assessed	1.9 (1.2-2.8)*	1.8 (1.2-2.7)	0.8 (0.3-2.2)	0.9 (0.3-2.3)
Charlson	1.0 (0.9-1.1)	1.0 (0.9-1.1)	1.0 (0.8-1.3)	1.4 (0.9-2.1)
Weight excess	0.6 (0.5-0.6)*	0.4 (0.3-0.5)*	1.0 (0.9-1.1)	1.0 (0.9-1.1)
Chronic diuretic	1.0 (1.0-1.0)	1.0 (1.0-1.0)	1.0 (1.0-1.0)	1.0 (1.0-1.0)
Initial diuretic	1.0 (1.0-1.0)	1.0 (1.0-1.0)	1.0 (1.0-1.0)	1.0 (1.0-1.0)
Continuous IV	1.7 (0.9-3.2)	5.1 (1.7-15.7)*	0.3 (0.1-2.1)	0.3 (0.1-2.4)
Elective admission	1.0 (0.6-1.8)	1.0 (0.5-1.6)	0.6 (0.1-2.7)	0.7 (0.1-3.1)
AKIN 1	0.9 (0.6-1.3)	0.9 (0.6-1.3)	1.7 (0.8-3.9)	1.6 (0.7-3.7)
AKIN 2	1.1 (0.5-2.6)	1.0 (0.5-2.3)	1.6 (0.6-4.7)	1.4 (0.5-4.2)
AKIN 3	1.1 (0.4-3.4)	1.2 (0.4-3.6)	-	-
Time varying covariates				
Reduced LVEF		0.8 (0.7-0.9)*		-
Weight excess		1.1 (1.0-1.2)*		-
Continuous IV		0.7 (0.5-0.9)*		-
Charlson		-		0.9 (0.8-1.0)

*p value <0.05
AKI: acute kidney injury; CPAP: continuous positive airways pressure therapy; I.V.: intravenous; LVEF: Left ventricular ejection fraction; UTI: urinary tract infection.




Figure S2.: log-minus-log plots for urinary catheter (UC) and the different time to event outcomes. Two tests were also used to assess the proportional hazard assumption: first the Schoenfeld residuals (**p value1**) and, second, the interaction between “urinary catheter” and time in a time-varying covariate cox regression (**p value2**). For the tow tests the p value need to be more than 0.05. **Panel A:** time to stop intravenous diuretic therapy; **Panel B:** time to stop oxygen supply; **Panel C:** time to reach target weight; **Panel D:** time to stop CPAP therapy; **Panel E:** time to death; **Panel F:** time to first hospital readmission; **Panel G:** time to first urinary tract infection.




Figure S3: Schoenfeld residuals plots over Time for urinary catheterisation (UC) and covariates in the model for time to reach target weight.




Figure S4: Schoenfeld residuals plots over Time for urinary catheter (UC) and covariates in the model of time for discontinue intravenous diuretic therapy.




Figure S5: Schoenfeld residuals plots over Time for urinary catheter (UC) and covariates in the model of time to discontinue CPAP.




Figure S6: Schoenfeld residuals plots over Time for urinary catheter (UC) and covariates in the model for time until oxygen supply discontinuation.




Figure S7: Schoenfeld residuals plots over Time for urinary catheter (UC) and covariates in the model for time to death.




Figure S8: Schoenfeld residuals plots over Time for urinary catheter (UC) and covariates in the model for time to first urinary tract infection.




Figure S9: Schoenfeld residuals plots over Time for urinary catheter (UC) and covariates in the model for time to first hospital readmission.

References:

1. Ezekowitz JA, O'Meara E, McDonald MA, Abrams H, Chan M, Ducharme A, et al. 2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. *Can J Cardiol* 2017;33(11):1342-433.
2. Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, et al. Diuretic strategies in patients with acute decompensated heart failure. *N Engl J Med* 2011;364(9):797-805.
3. Sanderson JE. Factors related to outcome in heart failure with a preserved (or normal) left ventricular ejection fraction. *Eur Heart J Qual Care Clin Outcomes* 2016;2(3):153-63.
4. DeVore AD, Hill CL, Thomas LE, Albert NM, Butler J, Patterson JH, et al. Identifying patients at increased risk for poor outcomes from heart failure with reduced ejection fraction: the PROMPT-HF risk model. *ESC Heart Fail* 2022;9(1):178-85.
5. Allison PD. *Survival analysis using SAS. A practical guide, second edition*. USA: SAS Institute Inc. Cary, NC, USA, 2010.
6. ter Maaten JM, Dunning AM, Valente MA, Damman K, Ezekowitz JA, Califf RM, et al. Diuretic response in acute heart failure-an analysis from ASCEND-HF. *Am Heart J* 2015;170(2):313-21.
7. Voors AA, Davison BA, Teerlink JR, Felker GM, Cotter G, Filippatos G, et al. Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome--an analysis from RELAX-AHF. *Eur J Heart Fail* 2014;16(11):1230-40.
8. Shah RV, McNulty S, O'Connor CM, Felker GM, Braunwald E, Givertz MM. Effect of admission oral diuretic dose on response to continuous versus bolus intravenous diuretics in acute heart failure: an analysis from diuretic optimization strategies in acute heart failure. *Am Heart J* 2012;164(6):862-8.
9. Schweiger A, Kuster SP, Maag J, Züllig S, Bertschy S, Bortolin E, et al. Impact of an evidence-based intervention on urinary catheter utilization, associated process indicators, and infectious and non-infectious outcomes. *J Hosp Infect* 2020;106(2):364-71.

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No.	Recommendation	Page No.	Relevant text from manuscript
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	1, 2	
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2,3	
Introduction				
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4	
Objectives	3	State specific objectives, including any prespecified hypotheses	5	
Methods				
Study design	4	Present key elements of study design early in the paper	5	
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5	
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	5-6	
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	10	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6-7	
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6-8	
Bias	9	Describe any efforts to address potential sources of bias	9 and supplements statistics	

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Study size	10	Explain how the study size was arrived at	supplements
			statistics

Continued on next page

For peer review only

1				
2	Quantitative	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which	9-10
3	variables		groupings were chosen and why	
4				
5	Statistical	12	(a) Describe all statistical methods, including those used to control for confounding	9-11
6	methods		(b) Describe any methods used to examine subgroups and interactions	NA
7			(c) Explain how missing data were addressed	6 and 9
8			(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed	10-11
9			<i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	
10			<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling	
11			strategy	
12			(e) Describe any sensitivity analyses	9 and
13				supplemental
14				statistics
15				
16				
17				
18	Results			
19	Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined	11-12,
20			for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	table1-2,
21				supplemental
22				flow chart
23			(b) Give reasons for non-participation at each stage	supplemental
24				flow chart
25			(c) Consider use of a flow diagram	supplemental
26				flow chart
27				
28				
29	Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on	Table 1
30			exposures and potential confounders	
31			(b) Indicate number of participants with missing data for each variable of interest	12
32			(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	Figure2-3
33				
34	Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	Figure2-3
35			<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	NA
36			<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
37				
38	Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision	Table2
39			(eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were	
40			included	
41				
42				
43				
44				
45				
46				

(b) Report category boundaries when continuous variables were categorized

(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period

Continued on next page

For peer review only

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	12 and supplemental data
Discussion			
Key results	18	Summarise key results with reference to study objectives	14
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	15-16
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	15-16
Generalisability	21	Discuss the generalisability (external validity) of the study results	16
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	21

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.